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Preface
For conventional genetic cloning, target genes are cleaved at restriction sites using 
restriction endonucleases. Researchers cannot modify genomic sites and it usu-
ally takes a lot of work, time, and patience to make and screen for desired clones. 
Current gene-editing technologies, including ZFNs, TALENs, and CRISPRs/
Cas9, can be utilized to engineer the genes of interest in living organisms with
unprecedented efficiency and precision, without the limitation of restriction site
availability. Specific and efficient genomic engineering has been performed in
human cells, microbes, plants, animals, etc. at will. Additionally, it has been applied 
in manufacturing products, including testing tools, agricultural products, foods, 
industrial products, medicinal products, etc. Among them, novel therapeutic
strategies based on gene-editing technologies are expected to bring hope for patient
recovery from serious diseases for which there are still no effective drugs or medical 
devices available.
Many biotechnology companies have successfully produced nonhuman therapeu-
tic products and medicinal products using gene-editing technologies. More and 
more products are being developed and approved for sale. Consequently, many
enterprises are encouraged to become involved in manufacturing products based 
on these technologies because of their perspectives for multiple applications. For
example, CRISPR has become an industry that is developing prosperously. These
enterprises also promote industry innovation through the transfer of technologies
and collaboration between academia and industry.
Gene-editing technologies are still being discovered and are expected to become
more mature, specific, efficient, and secure for applications in the near future.
The potential benefits of these revolutionary technologies are endless. However,
like any powerful tool, there are also associated challenges, including safety
and ethical/moral concerns, that need to be considered. Research and ethical
guidelines from national and international organizations will be critical for
funding agencies and institutional review boards to regulate these technolo-
gies, especially in the gene editing of human germ line cells and embryos. The
aim is to maximize the benefits and minimize the possible risks of gene-editing
technologies.
We wish all current and future research work, including the discovery, appli-
cations, perspectives, and challenges of gene-editing technologies, to have
a worthwhile impact on the betterment of human health. It is hoped that all
perspectives will become realities and any challenges will be overcome provided
that academia, industry, governments, and international societies constantly
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Gene editing is a type of genetic engineering in which DNA is inserted, deleted, 
modified, or replaced in the genome of a living organism. Unlike traditional meth-
ods that randomly insert genetic material into a host genome, current gene editing 
technologies target and change the specific genome locations. Zinc finger nucleases
(ZFNs), transcription activator-like effectors nucleases (TALENs), and clustered 
regularly interspaced short palindromic repeats (CRISPRs)/Cas9 nuclease system
are the three common gene editing technologies. These technologies have been
widely used in genome engineering to enable a broad range of mutation by inducing 
DNA breaks that stimulate error-prone repairs such as homologous recombination
(HR) or nonhomologous end joining (NHEJ). They successfully make it possible to
achieve site-specific editing, modification, and manipulation at specific genomic
sites (Table 1) [1].
1.1 ZFNs
ZFNs are artificial restriction enzymes generated by fusing a zinc finger-specific
DNA-binding domain to a nonspecific DNA cleavage domain. The specific binding 
domains of individual ZFNs typically contain between three and six individual 
zinc finger repeats and can each recognize between 12 and 18 base pairs. If the zinc
finger domains are specific for their intended target site, then even a pair of three-
finger ZFNs that recognize a total of 18 base pairs can target a single locus in a mam-
malian genome. The nonspecific cleavage domain from the restriction endonuclease
Fok I is typically used as the cleavage domain in ZFNs. This cleavage domain must
form a dimer in order to cleave DNA, and thus a pair of ZFNs are required to target
nonpalindromic DNA sites [2] (Figure 1).
1.2 TALENs
Transcription activator-like effectors (TALEs) are proteins secreted by bacteria
Xanthomonas via type III secretion system when they infect various plant species. 
TALEs are important virulence factors that act as transcriptional activators in the
plant cell nucleus [3]. Each TALE contains a central repetitive region consisting of
varying numbers of repeat units (about 17.5 repeats) of 34 amino acids [3, 4]. The
DNA-binding domain contains a highly conserved 34 amino acid sequence with
the exception of the 12th and 13th amino acids [3]. Only the 12th and 13th amino
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TALEs are important virulence factors that act as transcriptional activators in the
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Gene Editing - Technologies and Applications 
Technology ZFN TALEN CRISPR/Cas9 
Source Extensively exists in Plant pathogenic An adaptive immune
the nature bacteria Xanthomonas system in bacteria 
Targeting specificity Zinc finger protein TALE SgRNA 
determinant 
Nuclease Fok I Fok I Cas9 
Restriction for a target Rich in cytosine No special restriction PAM 
sequence 
Target site Two (left and right) Two (left and right) Only one 
Length of target gene 12–18 bp 12–18 bp 18–23 bp 
Mode of action Two proteins act on Two proteins act on two RNA and Cas9 act on
two target sites target sites one target site 
Cleavage site DSB with a sticky DSB with a sticky end DSB with a blunt end 
end 
Efficiency Medium Medium High 
Ease of engineering Low Medium High 
Ease of characterization Low Medium High 
Cost High Medium Low 
Cytotoxicity High Low Low 
Off target Yes Yes Yes 
Abbreviations: CRISPR, clustered regularly interspaced short palindromic repeat; DSB, double-strand break; Fok, 
Flavobacterium okeanokoites; PAM, protospacer adjacent motif; TALE, transcription activator-like effector; sgRNA, 
single guide RNA; and ZFN, zinc finger nuclease. 
Table 1.
Comparison of different gene editing technologies. 
Figure 1.
ZFNs are chimeric nucleases consisting of specific DNA-binding modules linked to a nonspecific cleavage 
domain. Right and left ZFNs containing Fok I endonucleases link to an array of 3–6 zinc fingers that have 
been designed to specifically recognize target sequences (12 green and 12 purple boxes), respectively. The ZFN 
targets are separated by typically 5 or 6 bp. Two Fok I work as a homodimer to cleave the sense strand 1 bp and 
antisense strand 5 bp downstream of the binding site. 
stable. These two locations—repeat variable di-residues (RVD) are highly variable
and show a strong correlation with a specific nucleotide recognition by differ-
ent frequency, for example, NI recognize A (55%), NG recognize T (50%), NN 
recognize G (7%), and HD recognize C(69%) [3]. Two amino acids have known to
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TALEs [3, 4]. The restriction endonuclease Fok I consists of an N-terminal specific
DNA-binding domain and a C-terminal nonspecific DNA cleavage domain. The
nonspecific DNA cleavage domain of Fok I cleaves the double-strand DNA (DSB) 
at a fixed distance of 9 and 13 nucleotides downstream of the recognition site [5]. 
TALENs are artificial restriction enzymes generated by fusing the specific TALE 
DNA-binding domain to a nonspecific Fok I DNA cleavage domain [6–8] (Figure 2). 
1.3 CRISPRs/Cas9 
The CRISPRs/Cas9 system, originally found in the bacteria, functions as an
adaptive immune system against foreign virus or plasmid DNA. CRISPRs are
DNA loci containing short repetitions of base sequences. Each repetition is fol-
lowed by short segments of spacer DNA from previous exposures to the foreign
DNA. CRISPR-associated protein (Cas9) is a DNA endonuclease whose structure is
bilobed, composed of target recognition domain and nuclease lobes. The nuclease
Figure 2.
The specific repeat variable Di-residues (RVDs) used to recognize each base are defined in the key (NI:A, 
NG:T, NN:G, and HD:C). Left and right TALEs recognize their target sequences and allow their associated Fok 
I endonucleases to work as a homodimer to cleave the sense strand 9 bp and antisense strand 13 bp downstream 
of the binding site. Binding of TALEs to the target sites allows Fok I to dimerize and create a double-strand 






















Gene Editing - Technologies and Applications 
Figure 3.
A crRNA/tracrRNA hybrid acts as a single guide RNA (sgRNA) to recognize their target sequences and allow 
Cas9 endonucleases to cleave the sense strand 3 bp and antisense strand 3 bp upstream of the protospacer 
adjacent motif (PAM) sequence. Binding of sgRNAs to the target sites makes Cas9 create a double-strand break 
(DSB) with blunt ends on target sequences. 
lobe contains nucleases RuvC, HNH, and a carboxyl-terminal domain for the
protospacer adjacent motif (PAM) recognition [9]. The Type II CRISPRs system is
currently limited to target sequences that are N12-20NGG, where NGG represents
the PAM sequence [10]. Any potential target sequence must have a specific PAM 
sequence on its 3′ end. The CRISPR locus consists of Cas9 endonucleases, CRISPRs
RNAs (crRNAs), trans-activating crRNAs (tracrRNAs), and precursor crRNAs
(pre-crRNAs). tracrRNA is partially complementary to and pairs with a pre-crRNA 
to form an RNA duplex cleaved by RNase III. The crRNA/tracrRNA hybrid acts as
a single guide RNA (sgRNA) for the Cas9, which cleaves the invading DNA. The
DNA target sites can appear in multiple locations, all of which will be targeted by
the Cas9 for cleavage. By delivering the Cas9 protein and appropriate sgRNAs into a
cell, the organism’s genome can be cut at most locations with the only limitation of
PAM availability (Figure 3). 
2. Application 
2.1 Tools for basic research 
2.1.1 Genetic cloning of living organisms 
For conventional genetic cloning of animals, plants, and microbes, the target
genes in the specific genome are cut using restriction enzymes. It usually takes lots
of work and long time to clone and screen for the desired ones. Current gene editing 
technologies can be used to achieve the desired clones both quickly and accurately, 
without the limitation of restriction site availability [11]. 
2.1.2 Establishment of animal models 
Genetic cloning, gene knock-in, and gene knockout are the most common
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include ZFNs, TALENs, and CRISPRs/Cas9. By these new gene editing technologies, 
specific animal models of many diseases for which there are no animal models avail-
able previously have been established with unprecedented efficiency and precision
[12–14]. 
2.1.3 Development of testing tools and reagents 
CRISPRs/Cas9 can be optimized by bacterial genotypes to be more adaptive
to the variation of food pathogens, compared with traditional methods. The
CRISPR locus of different bacterial species show high variance to be an ideal basis
for genotyping [15]. The CRISPR/Cas12a(Cpf1) DETECTR (DNA endonuclease
targeted CRISPR trans reporter) system can be used to diagnose gene mutations, 
cancers, and microbial infections and test microbial antibiotic resistance by analyz-
ing specimens [16]. 
2.1.4 Discovery of drugs 
The screening and identification of target sites are critical to drug discovery;
thus, excellent and suitable platforms are needed. Gene editing technologies
can work for the editing of functional genes and the screening of target sites.
For example, CRISPRs/Cas9 was used to target the exons encoding functional
protein domains. A screen of 192 chromatin regulatory domains in murine acute
myeloid leukemia (AML) cells identified 6 known drug targets and 19 additional
dependencies [17]. 
2.2 Nonhuman therapeutics 
2.2.1 Agricultural products 
The gene editing technology can be used to produce agricultural products in
accordance with the need of humans. For example, crops were produced with high
yield and resistant to diseases, insects, herbicides, and harsh environment [18, 19]; 
domesticated animals (pig, buffalo) were produced with double muscle phenotype
[20]; and aquatic products (catfish) were produced with high level myostatin
(MSTN) gene expression [21]. 
2.2.2 Food 
We can make food more productive or have longer shelf-life by gene editing 
technologies. For example, CRISPRs/Cas9 was used to edit thermophilic bacteria
Streptococcus thermophilus as a bacteriophage-insensitive mutant to improve the
product (e.g., yogurt, cheese) yield by refraining from the infection of phages [22]. 
The white button mushroom Agaricus bisporus was engineered to resist browning 
using CRISPRs/Cas9. The effect was achieved by targeting to knock out the genes
that encodes polyphenol oxidase—an enzyme that causes browning [23]. 
2.2.3 Industrial products 
CRISPRs/Cas9 has been used to establish marine algae (e.g., diatoms) as useful 
in industrial applications as the carbon neutral synthesis of fuels, pharmaceuticals, 
health foods, biomolecules, materials related to nanotechnology, and bioreme-
diations of contaminated water [24, 25]. CRISPRs/Cas9 was used to encode the
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genomes. By CRISPRs/Cas9, the technical limits of this information storage system
can be optimized to be minimal. CRISPRs/Cas9 can capture and stably store many
real data within the genomes of living cells [26]. 
2.2.4 Environmental protection 
Marine microalgae are in charge of about 40% of primary production on earth
and capture more CO2 than rain forests. Diatoms are the most important unicellular
eukaryotic microalgae and have dominant ecological significance. CRISPRs/Cas9 
can be used to modify the diatom genome to achieve more effects in reducing the
global warming [25]. 
2.2.5 Restoration of extinct animals 
Woolly mammoths are different from current living elephants by adapting
to the extreme cold environment. The mammoth TRPV3 gene, which encodes a
temperature-sensitive transient receptor potential (thermoTRP) channel involved
in thermal sensation and hair growth, could be achieved by modifying genes
of Asian elephants [27]. The mammoth may be restored using CRISPRs/Cas9,
if the modified embryo can be successfully transferred into the uterus of living
elephants. 
2.3 Human therapeutics 
2.3.1 Medicine screening 
The therapeutic strategies of Parkinson’s disease (PD) are quite variable includ-
ing drug and nondrug treatment. Therefore, it is necessary to find a suitable
strategy to treat PD safely, efficiently, and quickly. A novel tool was established for
monitoring endogenous alpha-synuclein (α-SYN) transcription by NanoLuc lucif-
erase tag insertion at the 3′ end using CRISPRs/Cas9, and thus making it possible to
screen for strategies rapidly that can be used for PD therapy efficiently [28]. 
2.3.2 Preparation for cell therapy or immunotherapy 
The gene-editing technology can be applied to engineer induced pluripotent
stem (iPS) cells and chimeric antigen receptor T (CART) cells. CRISPRs/Cas9 has
been used to engineer iPS cells to evade immune rejection in full immunocompetent
allogeneic recipients [29]. Because the CD19 CAR was successfully used in treat-
ment, CRISPRs/Cas9 may further enhance the efficacy and safety of CART cells by
engineering therapeutic T cells [30]. 
2.3.3 Potential application for disease treatment 
2.3.3.1 Virus latent infection 
Diseases caused by viruses are difficult to treat due to their high mutation rates
and latent infections. It is almost impossible to eradicate latent viruses in the human
host. However, TALENs and CRISPRs/Cas9 have been found to provide good strate-
gies in targeting viruses and limiting their productive and latent infections ex vivo
and/or in vivo, such as herpes simplex virus 1 (HSV-1), Epstein-Barr virus (EBV), 
human cytomegalovirus (HCMV), human immunodeficiency virus (HIV), and 
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2.3.3.2 Genetic disease 
Genetic diseases can be cured by gene therapies such as sickle cell anemia, 
β-thalassemia, muscular dystrophy, α1-antitrypsin deficiency, Leber congenital 
amaurosis, and cystic fibrosis [37]. The gene editing technologies (e.g., CRISPRs/ 
Cas9) potentially facilitate the progress of gene therapy, because many experiments
have been successful ex vivo and in vivo, and some of them are being under clinical 
trials. 
2.3.3.3 Neurodegenerative disease 
By applying the Perturbing Regulatory Interactions by Synthetic Modulators
(PRISM) to a yeast model of PD, sgRNAs were identified to modulate transcrip-
tional networks and protect cells from α-Syn toxicity [38]. The APPswe (Swedish) 
mutation in the amyloid precursor protein (APP) gene causes Alzheimer’s disease
(AD). The mutant APPSW allele can be selectively disrupted using CRISPRs/Cas9 
both ex vivo and in vivo and thereby decrease pathogenic amyloid-β (Aβ) [39]. 
2.3.3.4 Cancer 
CRISPRs/Cas9 were tried to inhibit hepatocellular carcinoma (HCC). miR-125b
can suppress the expression of SIRT6 by directly targeting the seed-matching region
of its 3′UTR. After the expression of SIRT6 knocked out through CRISPRs/Cas9, 
HCC cells showed the decreased viability and invasiveness, which had the similar
function upon the overexpression of the miR-125b [40]. CRISPRs/Cas9 was also
tried to inhibit breast cancer. Cyclin-dependent kinases (CDKs) are established 
anti-cancer drug targets, and a new generation of CDK inhibitors provides clinical 
benefits to the patients. Breast cancer cells were genetically manipulated using a
deactivated CRISPRs/Cas9 (dCRISPR) approach to strengthen the endogenous
CDK18 promoter to express highly to exhibit an increased sensitivity [41]. 
3. Conclusion 
The gene editing technologies, especially CRISPRs/Cas9, have been extensively
used as tools in basic research for genome encoding, silencing, enhancing, and 
modification. Currently, they are further applied in manufacturing nonhuman
therapeutic products and medicinal products. Particularly, the discovery of
medicinal products using gene editing technologies will open a new era for human
therapeutics and expect to bring a hope for patient recovery from being seriously
sick. Many biotechnology companies and pharmaceutical plants have successfully
produced products using gene editing technologies. For example, CRISPR has
become an industry which is prosperously developing recently. Nonhuman thera-
peutic products are usually manufactured nonexclusively, while human therapeutic
products are manufactured exclusively because they are highly technical, ethically
concerned, and more profitable. Gene editing technologies are very promising in
applications, though there are still many technical (e.g., off target effects, option of
delivery tools, localization of function) and ethical challenges (e.g., evaluation of
benefits and risks, compatibility of private interests and the public good, random
manipulation of genes, commercialization of human therapy) unsolved. More
and more products based on these technologies are approved for marketing. We
also expect the challenges of safety concerns (e.g., genetically modified organism, 
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Abstract
Pigs provide valuable meat sources, disease models, and research materials
for humans. However, traditional methods no longer meet the developing needs
of pig production. More recently, advanced biotechnologies such as SCNT and
genome editing are enabling researchers to manipulate genomic DNA molecules.
Such methods have greatly promoted the advancement of pig research. Three
gene editing platforms including ZFNs, TALENs, and CRISPR/Cas are becoming
increasingly prevalent in life science research, with CRISPR/Cas9 now being the
most widely used. CRISPR/Cas9, a part of the defense mechanism against viral
infection, was discovered in prokaryotes and has now developed as a powerful
and effective genome editing tool that can introduce and enhance modifications
to the eukaryotic genomes in a range of animals including insects, amphibians,
fish, and mammals in a predictable manner. Given its excellent characteristics
that are superior to other tailored endonucleases systems, CRISPR/Cas9 is suitable
for conducting pig-related studies. In this review, we briefly discuss the histori-
cal perspectives of CRISPR/Cas9 technology and highlight the applications and
developments for using CRISPR/Cas9-based methods in pig research. We will
also review the choices for delivering genome editing elements and the merits and
drawbacks of utilizing the CRISPR/Cas9 technology for pig research, as well as
the future prospects.
Keywords: applications, CRISPR/Cas9, delivery methods, gene editing, pig
1. Introduction
1.1 The status of pig production and current application of CRISPR/Cas9 
technology
Worldwide, pig (Sus scrofa domestica) production accounted for 42% of total
livestock production in 2018, and this percentage is expected to go up by the
year 2050 [1, 2]. Pork, which makes up nearly 40% of all meat consumed by the
world population, is clearly an important meat source for humans [3]. These
production and consumption data reveal the significant implications of pigs
for humans. Indeed, pigs bring many benefits for the convenience and survival
of human beings. In light of the importance and necessity for pig production,
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Gene Editing - Technologies and Applications 
Benefitting from the rapid development of genome-editing technologies during 
the last decade, many laboratories have applied this tool to animals, plants, and 
microorganisms in order to obtain both higher yield and better quality varieties. 
With the advent of the CRISPR (clustered regularly interspaced short palindromic
repeats)/Cas9 technique and the melioration of delivery methods, gene editing can
be more successfully performed in livestock such as swine. In addition, evidence
shows that, in addition to primates, pigs share many similar characteristics with
humans such as organ size, genome length, blood glucose levels, and the complexity
and composition of chromosomes [4, 5], as well as the early embryonic develop-
ment trajectory [6]. Therefore, pigs are not only used as important domestic
animals for food and pharmaceutical applications, but also served as ideal animal 
models for simulating various human diseases (e.g., diabetes, obesity, and cardio-
vascular disease). In this manuscript, we first introduce the historical perspectives
of gene-editing technologies in pigs, review the latest advances in the utilization of
CRISPR/Cas9 strategies for swine research, and then describe possible methods for
delivering these genome-editing components, as well as the future perspective on
pig studies by using this technology. 
1.2 Historical background of gene editing in pigs 
CRISPR, discovered in 1987, is a family of DNA sequences of short direct
repeats interspaced with short sequences. Its mechanism of action has been
confirmed to be related with acquired immunity of microbes [7–9]. By 2000,
researchers had discovered that these specific sequences occurred in about 40%
of bacteria and 90% of archaea [10, 11]. In 2002, this interesting architecture,
initially named short regularly spaced repeats (SRSRs), was renamed as the
clustered regularly interspaced short palindromic repeats (CRISPRs) [10, 12].
Between 2002 and 2009, a series of proteins associated with these palindromic
sequences were identified as constituents of the complicated mechanism of
microbial adaptive immunity [11]. In 2014, the X-ray crystal structure of
Streptococcus pyogenes Cas9 (SpCas9) in complex with sgRNA was elucidated
[13, 14]. Nowadays, SpCas9 endonuclease, which requires a protospacer adjacent
motif (PAM) sequence (5’-NGG-3′), is routinely designed as a ‘molecular scis-
sor’ guided by a single guide RNA (or dual-tracrRNA) due to simple structural
characteristics, the advantages of easy operation, and high efficiency [11, 15].
Notably, the multiplex abilities of the Cas9-associated guided RNAs (gRNAs) and
the diverse Cas9 orthologs (e.g., SpCas9, SaCas9, StCas9) as well as the diversified
Cas9 variants (Figure 1) have enabled CRISPR/Cas9 systems to be used in a wide
range of research applications [16, 17]. 
As early as 1985, the first transgenic pig was created by direct DNA microinjec-
tion of the metallothionein-I/human growth hormone (MT/hGH) fusion gene into
a fertilized egg [18]. Further technical enhancements occurred during the next
20 years, until, in 2011, Whitworth and his co-workers were the first to success-
fully apply ZFN technology to generate cloned eGFP knockout pigs [19]. Similarly,
Carlson et al. (2012) pioneered the application of TALENs in editing the porcine
genome, and they produced low-density lipoprotein receptor (LDLR) knockout
pigs [20]. By 2013, the groundbreaking work of genome engineering in mam-
malian cells based on the CRISPR/Cas9 system had been achieved [21]. The first
examples of genome-modified pigs engineered using the CRISPR/Cas9 technique
were reported almost simultaneously by Hai et al. (2014) [22] and Whitworth et al.
(2014) [23]. From then on, rapid and efficient CRISPR/Cas9-mediated genome
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Figure 1.
Diagram illustrating different types of engineered CRISPR/Cas9 and its Cas9 variants. (A) The wild-type 
SpCas9 nuclease. (B) The wild-type SaCas9 nuclease. (C) The wild-type NmCas9 nuclease. (D) The wild-
type StCas9 nuclease. (E) The dCas9 variant can bind DNA but cannot cut DNA strands. (F) The SpCas9 
nickase that can only introduce a single strand break at the HNH nuclease domain. (G) The SpCas9 nickase 
that can only introduce a single strand break at the RuvC nuclease domain. (SpCas9, Streptococcus pyogenes 
Cas9; SaCas9, Staphylococcus aureus Cas9; NmCas9, Neisseria meningitides Cas9; StCas9, Streptococcus 
thermophilus Cas9; dCas9, catalytically inactive (“dead”) Cas9; sgRNA, single-guide RNA; PAM, protospacer 
adjacent motif; W = A or T). Refer to [16]. 
2. Application and development 
2.1 Applications in the antimicrobial and antiviral fields 
Currently, the traditional methods for developing pig anti-viral vaccines are
time-consuming and labor-intensive [24]. Cas9 endonucleases, as molecular DNA 
scissors guided by gRNA, are now used to target and cut exogenous DNA arising 
from virus or plasmids [25]. With the development of state-of-the-art biotechnolo-
gies, scientists now can utilize this revolutional tool to prevent domestic pigs from
pathogenic bacterial and viral attack. In 2016, Liang and his colleagues developed a
rapid vaccine development method based on the combination of CRISPR/Cas9 and 
the Cre/Lox system to fight against the re-emerging pseudorabies virus (PRV). The
results demonstrated the protective efficacy of this candidate vaccine in swine and 
showed promise in controlling the outbreak of pseudorabies [26]. In another trial, 
Whitworth et al. (2015) employed the CRISPR/Cas9 system to directionally mutate
the CD163 gene (cluster of differentiation 163 gene, a gate keeper gene associated 
with PRRSV) in order to create biallelic gene knockout pigs which had protective
immunity against infection of porcine reproductive and respiratory syndrome
virus (PRRSV) [27]. In 2018, Xie and his co-workers applied the combinational 
method of CRISPR/Cas9 and RNAi to generate anti-CSFV transgenic pigs and 
confirmed that these pigs could impede the multiplication of classical swine fever
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transgenic sows could be stably transmitted to their F1-generation offspring. This
study suggested that the use of such transgenic pigs would offer potential benefits
over commercial vaccination, could substantially reduce CSFV-related economic
losses, and would also improve the well-being of livestock [28]. Compared to CSFV, 
African swine fever virus (ASFV) is a very acute, lethal viral pathogen for both
domestic and wild pigs, but unfortunately, a vaccine candidate that effectively
prevents ASFV infection remains elusive. HüBner et al. (2018) applied the CRISPR/ 
Cas9 nuclease system to target the double-stranded DNA genome of ASFV. In vitro
culture experiments showed that mediated targeting of the ASFV p30 gene using 
this system is a feasible strategy to fight against ASFV infection, and may also be
applied to the natural animal host [29]. 
2.2 Applications to breeding and reproduction 
Traditional breeding methods, which comprise selective breeding and cross-
breeding, have clearly hit a bottleneck. Additionally, due to the long time, high cost, 
and high labor intensity of traditional breeding methods [30], researchers now
hope to find other alternatives that are more convenient and efficient than previ-
ously. Genome-editing technology can help us to achieve a good result in a short
time, and help better understand swine reproduction. Interestingly, many aspects
of pig reproduction are suitable as translational models of reproduction in humans, 
including oocyte maturation, sperm-egg interaction mechanism, tubo-uterine
contractility, early embryo development, pregnancy, fetal genome modification, 
and reproductive diseases [31]. Strategies that use the CRISPR/Cas9 technique to
improve the reproduction in swine are becoming more prevalent. PRRSV, a virus
associated with reproductive and respiratory disease, can cause severe unsuccessful 
reproductive outcomes in sows, decrease sperm quality in infected boars, and lower
the birth rates of healthy piglets [32]. In 2016, Tao et al. generated efficient biallelic
mutation in porcine parthenotes by cytoplasmic injection of Cas9/sgRNA mixtures. 
These data emphasize the function of parthenotes in revealing early embryonic
development and assessing mutation efficiency [33]. In the same year, Whitworth
et al. used CRISPR/Cas9 to generate CD163-knockout pigs to protect pig from
PRRSV and reduce the incidence of reproductive disease, important for pig studies
in both the fields of reproduction and anti-viruses [27]. In 2017, Park et al. utilized 
CRISPR/Cas9 technology to program the NANOS2 gene in domestic pigs to gener-
ate offspring with monoallelic and biallelic mutations. They found that NANOS2 
knockout pigs presented the phenotype of male specific germ line ablation but
other aspects of testicular development were normal. The exception was male pigs
with one intact NANOS2 allele and female knockout pigs which both maintained 
good reproductive performance [34]. 
2.3 Applications in immunization and xenotransplantation 
Swines, having many highly similar anatomical and physiological features
to humans, are considered to be the excellent donors for patients in the case of a
shortage of human organs for allogenic transplantation [35, 36]. However, several 
issues still need to be addressed such as hyperacute rejection which can develop in
recipients within several minutes after organ xenotransplantations [36, 37]. The
advancement of the CRISPR/Cas9 technique has greatly strengthened the ability
to effectively manipulate porcine genome in order to evaluate and generate porcine
organs that can assist in xenotransplantation. 
An early study, undertaken by Sato and his research team in 2013, used a modi-
































Application and Development of CRISPR/Cas9 Technology in Pig Research 
DOI: http://dx.doi.org/10.5772/intechopen.85540 
product is responsible for the biosynthesis of the a-Gal epitope, which leads to
hyperacute rejection upon pig-to-human xenotransplantation. This trial not only
demonstrated that CRISPR/Cas9 is a promising tool for producing knockout cloned 
piglets, but also paved the way for pig-to-human xenotransplantation [38]. Piglets
with biallelic knockouts of GGTA1 gene were eventually created by Petersen and his
colleagues [39] using the combined technologies of CRISPR/Cas9 and somatic cell 
nuclear transfer (SCNT). 
Swine could also serve as an ideal animal model for investigating viral immu-
nity and immune rejection in xenotransplantation if they are deficient in class I 
MHC. Research published by Reyes et al. in 2014 utilized the Cas9 endonuclease
with chimeric gRNAs to generate class I MHC knockout piglets as promising 
experimental animals for immunological research [40]. In 2015, Yang and co-
workers designed two Cas9 gRNA molecules to inactivate 62 copies of the pol gene
required for porcine endogenous retrovirus (PERV) activity. This study performed 
on porcine kidney epithelial cell lines demonstrated that the modifications could 
greatly reduce in vitro spreading of PERVs to human cells, raising the hope of the
eradication of such viruses from pigs for heterograft donors [41]. One year later, 
Yang’s research team (2017) made further progress in employing CRISPR/Cas9 
technology to inactivate all the PERVs in a porcine primary cell line and produced 
PERV-eliminated pigs using the SCNT technique. The experimental results
addressed the safety problem in clinical xenotransplantation due to the success of
impeding interspecific transmission of viruses [42]. 
2.4 Disease models and translational medical research 
The CRISPR/Cas9 technology has both simplified and expedited biomedical 
modeling for some refractory human diseases. One way to combat human diseases
is to create genetically modified animal models for investigating the mechanism
of diseases enabling the development of safe and effective drugs. An effective
animal disease model should appropriately simulate the in vivo environment under
investigation and respond or react to stimuli in a similar manner to the human body
[43–45]. Commonly used animal models in the laboratory include mice, rats, dogs, 
monkey, and swine. The pig models have been developed to faithfully mimic vari-
ous human diseases including neurodegenerative diseases [46], cancers [45], and 
gastrointestinal (GI) tract diseases [47] as they share similar features to humans in
terms of anatomy, physiology, and genetics [43]. Gene editing using CRISPR/Cas9 
technology is proving an innovative and effective research tool, which is greatly
revolutionizing our ability to manipulate the porcine genome to create appropriate
disease models. 
As early as 2013, Tan et al. used two custom endonucleases (TALEN and 
CRISPR/Cas9 system) to edit azoospermia-like (DAZL) and adenomatous polyposis
coli (APC) loci in the pig genome. The results suggested that gene editing could 
be incorporated into selection programs to accelerate genetic improvement, with
applications in animal breeding and human personalized medicine [48]. In 2014, 
Zhou et al. were the first to report that zygote injection of a customized CRISPR/ 
Cas9 system could efficiently generate genome-modified pigs (biallelic knockout
pigs) in one step, which provided an important animal model for the treatment of
human type I and III von Willebrand disease [22]. At the end of 2015, Peng et al. 
adopted the CRISPR/Cas9 method to knockin human cDNA into the albumin
gene locus in pig zygotes and successfully produced human albumin from porcine
blood [49]. Additionally, Feng et al. (2015) reported the potential of using the
combination of CRISPR/Cas9 and human pluripotent stem cells (PSCs) to harvest
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which Cas9 mRNA and multiple single guide RNAs (sgRNAs), which respectively
specifically target to parkin, DJ-1, and PINK1 gene loci, were coinjected into in vivo
derived pronuclear embryos of Bama miniature pigs. There were only minor low
off-target events. These results demonstrated the capability of using the CRISPR/ 
Cas9 system to trigger genetic modification of multiple sites in pigs, yielding 
positive results with high medical value [51]. In the same year, Lee and his team
utilized genome-specific CRISPR/Cas9 systems to target runt-related transcription
factor 3 (RUNX3, a known tumor suppressor gene) to generate a pig model that can
recapitulate the pathogenesis of RUNX3-associated stomach cancer in humans. The
results demonstrated that the CRISPR/Cas9 system was effective in inducing muta-
tions on a specific locus of the pig genome, resulting in the generation of piglets
lacking RUNX3 protein in their internal organs. This system brings useful resources
(RUNX3 knockout pigs) for human cancer research and the development of novel 
cancer therapies [52]. In 2017, Zhang et al. designed an experiment that applied the
CRISPR/Cas9 system and SCNT technology to generate complement protein C3 
targeted piglets, which could be a valuable large animal model for elucidating the
roles of C3, a protein of the immune system that plays a central role in the comple-
ment system and contributes to innate immunity [53]. By 2018, following many
years’ efforts, scientists have now made significant progress in using CRISPR/Cas9-
mediated knockin techniques to produce a Huntington’s disease (HD) pig model, 
which assists in the investigation of the pathogenesis of neurodegenerative diseases
and the development of appropriate therapeutics [54]. Recently (2018), Cho and 
co-workers successfully used the CRISPR/Cas9 and SCNT technologies to gener-
ate INS knockout pigs (insulin-deficient pigs) and demonstrated the efficacy of
the CRISPR/Cas9 system in producing pig models for use in diabetes research and 
pharmaceutical testing [55]. 
2.5 Improvement of meat quality and food safety 
Pig meat quality is controlled by multiple factors. To some extent, genetics are
considered as the dominating factor influencing pork quality in the pig industry, 
although environmental conditions can also potentially influence the porcine genet-
ics in the long term. In addition, fat and lean meat contents are both important for
the palatability of the pork [56, 57] and diet considerations. Consequently, scientists
now propose to improve pork traits to cater for the taste of the general public by
using gene-editing technology. In 2016, Bi et al. constructed isozygous, functional 
myostatin (MSTN) knockout cloned pigs without selectable marker gene (SMG) by
combined use of CRISPR/Cas9 and Cre/LoxP. The results showed that compared 
to the control group, the skeleton muscles were more pronounced and the back
fat thickness decreased slightly in such gene-edited pigs [58]. In 2017, Zheng et al. 
established a CRISPR/Cas9-mediated homologous recombination-independent
approach to efficiently insert mouse adiponectin-UCP1 into the porcine endog-
enous uncoupling protein 1 (UCP1) locus. The resultant UCP1 knockin pigs showed 
an enhanced ability to control their body temperature during acute cold exposure, 
lower fat deposition, and increased carcass lean meat [59]. In 2018, Xiang et al. used 
CRISPR/Cas9 technology to effectively edit insulin-like growth factor 2 (IGF2) 
intron 3–3072 site as the method of choice for the improvement of meat production
in Bama pigs. The result showed that it was the first time to demonstrate that edit-
ing a noncoding region can ameliorate economic traits in livestock [60]. 
CRISPR/Cas9 gene-editing technology has multiple benefits. In gene detection
fields, Zhou et al. developed a CRISPR/Cas9-triggered nicking endonuclease-
mediated strand displacement amplification method (namely CRISDA) for
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powerful isothermal tool for ultrasensitive and specific detection of nucleic acids in
pig pathogeny detection and food safety. Consequently, by making good use of this
precision editing engineered technology in agriculture, a reliable avenue for elite
swine production could be guaranteed, potential biological risks can be minimized, 
and a higher food safety can be protected. 
2.6 Applications in transgenesis and beyond 
Pig transgenesis is an important facet for functional investigation of biological 
pathways, as well as for biotechnology in animal husbandry. As a promising tool, 
CRISPR/Cas9 now has the ability to accelerate the process of pig transgenesis. 
Several studies have successfully constructed a CRISPR/Cas9 system for targeting 
the pig GGTA1 gene [38, 39, 62]. Ruan et al. (2015) inserted a gene fragment larger
than 9 kb at the newly named pH 11 genomic locus using CRISPR/Cas9 technology
and then confirmed that it was highly expressed in cells, embryos, and animals
[63]. Similarly, Zhou et al. (2015) worked on CRISPR/Cas9-mediated gene target-
ing in porcine fetal fibroblasts (PFFs), in which TYR, PARK2, and PINK1 loci were
effectively edited [64]. In 2016, Yang and colleagues edited the porcine INS (pINS) 
gene in fibroblasts by using TALENs or CRISPR/Cas9 [65], and in 2017, Zheng et al. 
inserted a mouse adiponectin-UCP1 gene efficiently into the porcine endogenous
UCP1 locus by the utilization of a CRISPR/Cas9-mediated homologous recombina-
tion-independent approach [59]. In the same year, Wang et al. applied the com-
bined system of Cre recombinase and Cas9/sgRNAs to simultaneously inactivate
five tumor suppressor genes (TP53, PTEN, APC, BRCA1, and BRCA2) and activate
one oncogene (KRAS) to develop a rapid lung tumor model in pigs [66]. By 2018, 
Whitworth et al. had developed a method that utilized the CRISPR/Cas9 technol-
ogy to remove a loxP flanked neomycin cassette by direct zygote injection of RNA 
encoding Cre recombinase. This new technique can be used to efficiently remove
selectable markers in genetically engineered animals without the need for long-term
cell culture and subsequent somatic cell nuclear transfer (SCNT) [67]. Almost
certainly, it has a very promising future for transgenic pigs with the advantages of
enhancing body growth and minimizing environmental pollution that would be
created by the CRISRP/Cas9 method. Table 1 shows applications of CRISRP/Cas9 
technology in transgenic pigs. 
3. Delivery methods of CRISPR/Cas9 
3.1 The appropriate choices for delivery: viral systems or nonviral platforms? 
In order to introduce precise and efficient genome modification, the proper
delivery modalities of CRISPR/Cas9 genome-editing materials are a crucial factor in
the generation of genetically engineered pigs. A variety of strategies have been used 
for delivering the CRISPR/Cas9 system which can be mainly divided into viral and 
nonviral delivery methods (Figure 2) [82]. 
Viral systems are the traditional tools that have been widely used for deliv-
ering genome editing materials (DNA or mRNA). To-date, three viral vectors
including lentivirus [83], adenovirus, and adeno-associated virus (AAV) have
been used for delivery of CRISPR/Cas9 components in various biological stud-
ies [84, 85]. However, there are several limitations associated with viral vectors
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Figure 2.
Delivery techniques for the CRISPR/Cas9 system. (iTOP: induced transduction by osmocytosis and 
propanebetaine; AAV: adeno-associated virus). 
Nonviral platforms for transferring the CRISPR/Cas9 components can be
achieved by physical and chemical approaches. In contrast to viral vectors, non-
viral vectors have lower immunogenicity, are not constrained by packaging sizes,
are facile to synthesize, and are capable of carrying multiple sgRNAs simultane-
ously [86, 87]. In nonviral methods, genome editing reagents are delivered either
as mRNA or as a combination of Cas9 endonuclease and sgRNA. To date, nonviral
methods available include microinjection, electroporation [88], hydrodynamic
injection, lipid particles, nanoclews, zwitterionic amino lipid (ZAL) nanopar-
ticles, and iTOP as well as the combinations of viral and nonviral methods [82].
Herein, we compared the various methods for delivering the CRISRP/Cas9 system
(Table 2). 
Delivery methods of gene modification in the field of pig research have even
used sperms as vectors for foreign genes (e.g. sperm-mediated gene transfer
(SMGT), and intracytoplasmic sperm injection (ICSI)-mediated gene transfer), 
and delivery strategies such as retroviruses and lentiviruses are still current [100]. 
Somatic cell nuclear transfer (SCNT), a technique that consists of taking an enucle-
ated oocyte and then implanting a donor nucleus from a somatic cell, is a remark-
able breakthrough in the history of swine genetic engineering [101, 102]. SCNT
combined with the rapid development of gene editing technologies such as TALENs
and CRISPR/Cas9 has excellent prospects. 
3.2 Challenges for delivering the CRISPR/Cas9 systems 
The CRISPR/Cas9 system has been applied to genome modification in a variety
of microorganisms, plants, and animals (including pigs), but the efficient transfer
of such system is still a challenge that affects the precise genome-editing activ-
ity [103]. If the CRISPR/Cas9 systems are to effectively function in the targeted
cells or organisms, choosing a suitable delivery system is of critical importance.
According to existing research, the CRISPR/Cas9 system can be broadly divided
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Delivery modes Advantages Limitations Text 
refs 
Lentivirus Broad cell tropism; large
capacity; long-term gene
expression 
Prone to insertional mutagenesis;














Limited packaging size; potential





Electroporation High transfection efficiency;
suitable for all types of
CRISPR-Cas9 











Microinjection Highly specific and
reproducible 
Time-consuming; suitable









Low delivery efficiency [94],
[92] 
Gold nanoparticles Membrane-fusion-like delivery Nonspecific inflammatory
response; potential toxicity 
[89],
[98] 
iTOP Use for the delivery of Cas9
protein and sgRNA 








Comparison of different delivery methods for CRISPR/Cas9 system. 
sgRNA, and CRISPR/Cas9 plasmid. Different CRISPR/Cas9 formats cooperate
with special transport vehicle to complete the transportation task for gene-editing
elements. Some research studies indicate that CRISPR/Cas9 ribonucleoprotein
(RNP) delivery seems to exceed gene delivery as it provides multiple function
advantages: short-term delivery, no insertional mutagenesis, minimal immuno-
genicity, and low off-target effect [87]. As previously mentioned, viral vectors
usually have their own limitations to be overcome compared to nonviral vectors.
However, nonviral vectors are generally used for in vitro genome editing studies
due to their biological incompatibility or cytotoxicity [95]. Recently, developing
efficient and biocompatible nonviral vectors (e.g., liposome and nanocarrier) has
just emerged, and achievements have been made. For example, a low cytotoxic
cationic polymer has been proven to mediate efficient CRISPR/Cas9 plasmid
delivery for genome editing [92]. In addition, a research article presented that
lipid-based Cas9 mRNA delivery has lower off-target effects than lentivirus-
packaged Cas9 mRNA transportation [104]. Generally speaking, the packag-
ing modes and delivery tools are two biggest factors that affect efficiency of
the CRISPR/Cas9 system apart from this system itself. In order to describe the
possible challenges for delivering the CRISPR/Cas9 system and the strategies used
to overcome these challenges, we form a table to illustrate in detail (Table 3) and
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Challenges Delivery methods Strategies Text 
refs 
Off-target effects Both in viral and nonviral
vectors; using plasmid-
based system 
Engineering high specificity Cas9
protein; optimizing sgRNA design;
proper selection of targeting site 
[105],
[94] 
Packaging challenges AAV (~4.7kpb), adenovirus,
lentivirus (~10kpb) 
Nonviral vectors have no packaging













Mosaic genotypes Microinjection Stimulating the HDR pathway; use
of Cas9 nickase 
[108] 
Immunogenicity AAV, adenovirus, lentivirus,
retrovirus 










Need to be further optimized;




Systemic delivery Viral and nonviral vectors Difficult to achieve through




Targeted delivery Nonviral vectors Viral vectors provide tissue tropism [110] 
Table 3.
Challenges for delivering the CRISPR/Cas9 system and the strategies that respond to these challenges. 
4. Discussion 
CRISPR/Cas9 technology is not only simple and easy to perform, but also has
significantly improved performances for mutational studies, which has accelerated 
the application of the CRISPR/Cas9 toolkit [68, 111]. However, there are still some
limitations and difficulties in the use of the CRISPR/Cas9 system for pig research. 
1. The CRISPR/Cas9 system itself is not flawless, and its off-site concerns vary in
different biological species [112, 113]. In addition, if the design and construc-
tion of sgRNA are not ideal, off-target editing of the genomic DNA can easily
occur. With more available datasets of CRISPR/Cas9, more newfangled tools
for designing sgRNA will be developed to lower the off-target effects. 
2. In pigs, complex traits associated with multiple genes enhance the difficulties
of using CRISPR/Cas9 to simultaneously and precisely edit and program DNA 
in the porcine genome. 
3. Complex environmental factors including water sources and feed qualities, as
well as animal husbandry production methods, as a range of external stimuli, 
could collaboratively affect CRISPR/Cas9-derived pigs in the long-term. 
4. Strategies and timing for delivering CRISPR/Cas9 systems need to be opti-
mized to control the ratio of HDR to NHEJ in order to enhance the efficiency
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5. Cytotoxicity produced by the CRISPR/Cas9 system and toxic response to
CRISPR/Cas9 in mammalian cells has become an issue that must be taken into
account. Recently, there have been reports that DSBs induced by Cas9 triggered a
P53-dependent toxic response that reduced the editing efficiency when applying
the CRISPR/Cas9 system to human programmed cells [114, 115]. Corresponding
studies on pigs have not yet been undertaken, but the human studies provide
some useful lessons for the development of pig research on genome editing. 
6. Using the resulting fetuses or newborns edited by CRISPR/Cas9 for screen-
ing of effective clones is time-consuming and laborious [80]. Probably, the
method of T7E1 assay for detecting insertion/deletion (INDEL) mutations in
blastocysts could help researchers to save time and money [80]. 
5. Conclusion 
Over the past few years, genome-editing technology clearly allows scientists to
produce genetically engineered pigs that are healthier to consume and more resis-
tant to diseases in an efficient way. Nowadays, the use of the CRISPR/Ca9 technique
on pigs in immunity, autoimmunity, obesity, aging, etc. is increasingly expanding 
and showing advantages over the conventional methods. In addition, another
version of CRISPR named CRISPR/Cpf1 was discovered in microbes, which fur-
ther expanded the CISPR toolkit, and holds promise to be applied in pig research. 
CRISPR/Ca9-modified pigs are providing a better perspective for understanding 
various aspects of pig biology and are paving the way for advancing the fields of
basic biology, translational medicine, biomedicine, and drug development. 
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CRISPR/Cas9 is widely used for genome editing in a variety of organisms, 
including mammals, fishes, and plants. In mammals, zygotes are considered an
appropriate target for gene delivery of CRISPR/Cas9 components [Cas9 endonucle-
ase and a single-guide (sgRNA)] via microinjection or in vitro electroporation. 
However, these approaches require ex vivo handling of zygotes, which is necessary
for egg transfer to recipient females to allow the treated zygotes to develop full-
term. These procedures are often laborious, time-consuming, and use numerous
mice. In our previous experiments, the plasmid DNA encapsulated by liposomal 
reagent introduced into the internal portion of a testis can be transferred to the
mature sperm present in the epididymal ducts, and is finally transferred to oocytes
via fertilization. Although it was not integrated into their genome, this approach
would be useful for creating genome-edited animals, since CRISPR/Cas9 can be
performed by transient interaction of Cas9 and sgRNA, whereby chromosomal 
integration of the CRISPR components is not a prerequisite. Here, we will review
past achievements concerning in vivo transfection of immature/mature sperm and 
present experimental proposals for possible genome editing via gene-engineered 
sperm based on recent findings.
Keywords: sperm, CRISPR/Cas9, guide RNA, testis-mediated gene transfer,
in vivo transfection, genome editing, vas deferens, epididymis, artificial insemination,
intratesticular injection
1. Introduction
Transgenesis is a method to induce genetic change in an organism by deliver-
ing exogenous DNA (also called transgenes) to early embryos (i.e., zygotes), and 
is now considered an important technique to examine gene function in vivo and 
for creating animal models of human disease [1, 2]. In 1980, Gordon et al. [3] first
demonstrated that microinjection of purified DNA fragments into the pronuclei 
of zygotes led to the production of mice carrying the transgenes, which are gener-
ally referred to as transgenic (Tg) or genetically modified (GM) mice. When the
injected transgenes are successfully integrated into the host chromosomes of the
zygotes, they are transmitted to the next generation through mating with normal 
mice in a Mendelian ratio, and gene expression derived from the integrated trans-
genes will occur in the Tg offspring depending on the property of the promoter











































Genome-Edited Animals Using 
Gene-Engineered Sperm 
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Abstract 
CRISPR/Cas9 is widely used for genome editing in a variety of organisms, 
including mammals, fishes, and plants. In mammals, zygotes are considered an
appropriate target for gene delivery of CRISPR/Cas9 components [Cas9 endonucle-
ase and a single-guide (sgRNA)] via microinjection or in vitro electroporation. 
However, these approaches require ex vivo handling of zygotes, which is necessary
for egg transfer to recipient females to allow the treated zygotes to develop full-
term. These procedures are often laborious, time-consuming, and use numerous
mice. In our previous experiments, the plasmid DNA encapsulated by liposomal 
reagent introduced into the internal portion of a testis can be transferred to the
mature sperm present in the epididymal ducts, and is finally transferred to oocytes
via fertilization. Although it was not integrated into their genome, this approach
would be useful for creating genome-edited animals, since CRISPR/Cas9 can be
performed by transient interaction of Cas9 and sgRNA, whereby chromosomal 
integration of the CRISPR components is not a prerequisite. Here, we will review
past achievements concerning in vivo transfection of immature/mature sperm and 
present experimental proposals for possible genome editing via gene-engineered 
sperm based on recent findings. 
Keywords: sperm, CRISPR/Cas9, guide RNA, testis-mediated gene transfer,
in vivo transfection, genome editing, vas deferens, epididymis, artificial insemination,
intratesticular injection 
1. Introduction 
Transgenesis is a method to induce genetic change in an organism by deliver-
ing exogenous DNA (also called transgenes) to early embryos (i.e., zygotes), and 
is now considered an important technique to examine gene function in vivo and 
for creating animal models of human disease [1, 2]. In 1980, Gordon et al. [3] first
demonstrated that microinjection of purified DNA fragments into the pronuclei 
of zygotes led to the production of mice carrying the transgenes, which are gener-
ally referred to as transgenic (Tg) or genetically modified (GM) mice. When the
injected transgenes are successfully integrated into the host chromosomes of the
zygotes, they are transmitted to the next generation through mating with normal 
mice in a Mendelian ratio, and gene expression derived from the integrated trans-
genes will occur in the Tg offspring depending on the property of the promoter
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are required for the “ex vivo handling of embryos,” including: collection of zygotes, 
DNA microinjection using an expensive micromanipulator, temporal incubation of
the injected zygotes, and egg transfer (ET) to the oviducts of the pseudo-pregnant
females to allow full-term development of the injected eggs [4, 5]. Furthermore, 
all of this requires highly specialized and skilled personnel for the preparation of
pseudo-pregnant females and vasectomized males, which is time-consuming and 
tedious, and requires a large number of mice. 
Since 1980, several methods for bypassing microinjection-based transgenesis
have been provided, which include infection of zygotes with viral vectors like a
retrovirus [6, 7], embryonic stem (ES) cell-based gene transfer [8–10], transgenesis
via somatic cell nuclear transfer [11–13], and intracytoplasmic sperm injection
(ICSI) using sperm associated with the transgene (TransICSI) [14, 15]. All of these
methods deal with zygotes and require ex vivo handling of embryos, although a
micromanipulator system is not used in almost the cases. 
Genome-editing via Oviductal Nucleic Acids Delivery (GONAD) is a recently
developed method for creating GM mice and rats without ex vivo handling of
embryos [16–21]. It can be simply performed by injecting a solution containing 
nucleic acids into the oviductal lumen of pregnant females at zygote to two-cell 
stages and subsequent in vivo electroporation (EP) to enhance DNA uptake by early
embryos in situ. In this case, there is no need for the large number of mice that is
normally required for the traditional microinjection-based transgenesis: only four
to five pregnant females are required for modifying an endogenous gene [18]. Thus, 
creation of GM animals is simplified with the development of GONAD, but an
expensive apparatus electroporator is still required for the technique. 
In 1989, Lavitrano et al. [22] reported the simplest, convenient, and cost-effective
method to create GM animals, which was called sperm-mediated gene transfer
(SMGT), where isolated sperm were incubated in the presence of naked plasmid DNA
for a short period and these DNA-associated sperm were subjected to in vitro fertiliza-
tion (IVF) with normal oocytes. The resulting progeny are later judged as those carry-
ing the exogenous DNA in their genome. Since the report, there has been controversy
over its reproducibility among researchers [23–25]. However, several recent improve-
ments were made on this SMGT system by several researchers who employed reagents
capable of enhancing gene delivery towards isolated sperm [26–28]. For example,
Shen et al. [29] incubated mouse sperm in a solution containing 3% dimethyl sulfoxide
(DMSO) and plasmid DNA for 10–15 min at 4°C prior to IVF. Embryos (42%; 25/60)
obtained from this experiment showed bright enhanced green fluorescent protein
(EGFP)-derived fluorescence. Furthermore, Kim et al. [30] reported that nanopar-
ticles, such as magnetic nanoparticles, can be a vehicle for delivering exogenous
DNA to sperm from various animals such as boar. They incubated boar sperm in the
presence of 0.5% (v/v) of magnetic nanoparticles (MNPs) and plasmid DNA coding
for green fluorescent protein (GFP) on the magnetic field for 90 min, and the magne-
tofected sperm were subjected to IVF with normal oocytes. As a result, they obtained
fertilized eggs expressing GFP. Unfortunately, for further development of IVF-derived
embryos, it still required ET towards recipient females, which is laborious and requires
specialized skill. Notably, it is possible to perform artificial insemination (AI) using in
vitro-transfected sperm, which can be simply done by injecting those sperm into the
uterine horn or lumen of the oviducts of recipient females showing oocyte ovulation.
This method, called “SMGT-based AI” (SMGT-AI), has already been performed by
several laboratories and will be discussed in more detail in the last part of this paper. 
Testis-mediated gene transfer (TMGT) is the in vivo version of SMGT, in which
sperm is transfected in vivo. This technology was first developed by Sato et al. [31],
who performed intratesticular injection of calcium phosphate-precipitated plasmid
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to epididymal sperm or spermatogenic cells within a seminiferous tubule (ST) of the
testis, and those transfected sperm will transmit it to an oocyte through fertiliza-
tion (Figure 1). They could detect the injected DNA in isolates of sperm from the
epididymis and from the uteri of females mated with the injected males, but the
DNA could not be detected in embryos [31]. In contrast with SMGT, TMGT does
not require ex vivo handling of embryos such as collection of oocytes, IVF and ET. In
this context, TMGT appears to be more convenient and simpler than SMGT for the
purpose of GM animal production. Since the report of Sato et al. [31], several in vivo
gene delivery approaches targeted to male reproductive systems have been reported:
gene delivery to spermatogenic cells by intratubular injection of STs (ST-mediated gene
transfer, STGT) (Figure 2a), to epididymal sperm present in the epididymal ducts
(epididymis-mediated gene transfer, EpiGT) (Figure 2b), and to sperm present in
the vas deferens (vas deferens-mediated gene transfer, VDGT) (Figure 2c). 
Based on this background, the previous terminology TMGT appears to be now
recognized as “direct in vivo gene delivery approach towards male reproductive
system.” In this context, it may be better to re-name TMGT as “intratesticular
injection-based gene transfer” (IIGT), which involves direct injection of genetic
materials into the interstitial space of a testis. Thus, IIGT, STGT, EpiGT and VDGT
can be considered as TMGT-related experiments. In Table 1, a summary of previ-
ous studies on TMGT-related experiments is listed. Furthermore, there are several 
excellent papers reviewing the SMGT/TMGT-related studies [28, 90–93], which
provide a helpful survey of this field. 
Figure 1.
IIGT in mice. To perform IIGT, at least three different ways to inject a DNA-containing solution into the testis 
have been employed. The first way (shown in a) is to perform IIGT towards a testis (that is exposed outside 
after surgery) under anesthesia [31, 32]. The second way (shown in b) is to perform IIGT through insertion of
a needle via scrotum under anesthesia [33]. The third way (shown in c) is to insert a needle at three times to 
different sites [34]. In these latter two cases, no surgery is required. Three to five days after IIGT, the IIGT-
treated males are subjected to mating with normal estrous females. The in vivo transfected sperm may fertilize 
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Figure 2.
There are several routes for introducing exogenous DNA into the male reproductive system. The routes for DNA 
injection are as follows: (a) STGT via rete testis; (b) EpiGT by inserting a glass pipette into the proximal region 
of caput epididymis; (c) EpiGT by inserting a glass pipette into the proximal region of cauda epididymis; and 
(d) VDGT by inserting a glass pipette into the proximal region of vas deferens. 
Method Species DNA/transfection method Outcome (note) References 
IIGT Mice Plasmid/calcium phosphate The exogenous DNA was
detectable in the sperm
isolated from caput and cauda
epididymides as early as 6 h after
IIGT and in the ejaculated sperm
from the female uteri, but not in
1-cell eggs 
[31] 
IIGT Mice Plasmid/liposome/IIGT 3
times at 4-day intervals 
Eighty percent of blastocysts
expressed lacZ from the exogenous
DNA, suggesting successful
transmission of the exogenous
DNA to F0 offspring 
[34] 
IIGT Rats Adenovirus Leydig cells expressed the
transgene 
[35] 
IIGT Mice Plasmid/EP Some spermatogenic-like cells
expressed the transgene 
[36] 
IIGT Mice Plasmid/liposome/2–5 days
after IIGT, the males were
mated to females 
Transmitted the foreign DNA
to F0 offspring at frequencies
of 4.3–92.3%; the copy number
of the exogenous DNA was
estimated to be less than 1 copy
per diploid cell; no transgene
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Method Species DNA/transfection method Outcome (note) References 
IIGT Mice Plasmid/liposome/2 days after
IIGT, the males were mated
to females 
Transmitted the foreign DNA to [33] 
F0 offspring at frequencies of
50.0–84.6%; expression of lacZ 
in most (71.9%) blastocysts, but
no expression of foreign DNA in
the mid-gestational F0 fetuses; 
transmission of the exogenous
DNA from F0 to F1 generation
at frequencies from 16.1–23.1%, 
suggesting that the introduced 
DNA was chimeric in these F0 
mouse testes 
IIGT Mice/rats Plasmid/liposome/3–4 days
after IIGT, the males were
mated to females 
Transmitted the foreign DNA to
F0 offspring at frequencies of 18%
in rats and 20% in mice; transgene
expression in F0 offspring;
transmission of the exogenous







IIGT, the males were mated
to females 
Plasmid/liposome/2 days after
IIGT, the males were mated
to females 
Detection of exogenous DNA in
the head and tail of epididymal
sperm; also, in the ejaculated sperm
isolated from the female uteri;
failure to detect the exogenous
DNA in the DNase-treated sperm,
suggesting no integration of the
transgene in sperm DNA 
Although seven commercially
available transfection reagents were
tested for possible improvement
of IIGT to increase copy number
of transgenes integrated and
transgene expression, drastic
improvement failed; transgene
expression indeed occurred, but the
degree of its expression diminished
with development; choice of
reagents used appears not to be so
critical for IIGT 
[38] 
[39] 
IIGT Rats Plasmid/liposome/4 days after
IIGT, the males were mated
to females 
Detection of foreign DNA [40] 
(encapsulated by DMRIE-C and
SuperFect among eight liposomes
tested) in sperm in the cauda
epididymis isolated 1, 4, and
14 days after IIGT; more than
80% of morulae expressed EGFP;
the ratio of animals carrying
the foreign DNA decreased as
they developed, suggesting high
incidence of mosaicism 
IIGT Mice Plasmid (lacZ/retroviral
integrase gene)/EP 
One month after IIGT, some [41] 
spermatocyte-like cells in
STs expressed the lacZ gene; 
co-transfection with integrase
gene resulted in prolonged 
expression of lacZ, suggesting 
the usefulness of integrase
gene co-transfection for stable
transformation of spermatogenic
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Method Species DNA/transfection method Outcome (note) References 
IIGT Mice TB or Hoechst 33342/ 
plasmid/EP 
TB was rapidly transported to [42] 
the epididymal portion after
IIGT; TB reached the corpus and
cauda epididymis within 2–4 days
after injection; sperm isolated
from epididymal portion had
the exogenous DNA even after
DNase I treatment, suggesting
incorporation of the DNA inside
the sperm 
IIGT Mice Adenovirus Presence of the transgenes in sperm
from 7 to 16 days after inoculation;
transgenes are detected in the
sperm heads in oocytes after IVF;
the transgene product was mainly
present in the interstitial tissue of a
testis; it was also present in the STs
and collected sperm; the transgene
product was located in the head and





Plasmid/liposome IIGT was performed 48 h before
spawning. After mating these IIGT-
treated males to females, between
59 and 76% of the hatched fry were
found to be Tg; the efficiency of
gene transfer was improved more
than 80% by injecting multiple
doses of the transgenes; Southern
blot analysis showed that the
transgene was integrated into the
host genome 
[44] 
IIGT Mice Plasmid/EP To study regulatory elements
of genes specifically active in
spermatocytes, IIGT-EP was
performed; in the EP-based IIGT-
treated testes, only small fraction
of cells expressed the transgenes;
this method can be useful for
preliminary screening of constructs






Adenovirus/IIGT at 3 sites
per testis 
Plasmid/liposome/repeated
injections (singly, 3 or 6 ti
3 days apart) 
The transgene expression was
found in Leydig cells, but no
expression was noted in germ cells 
Repeated injections of the
mes exogenous DNA led to a high rate of
gene transfer, but failed to introduce
high numbers of copies (more than
1 copy per diploid cell); expression
of transgene-derived mRNA was
observed, although its strength
appeared still to be very low 
[46] 
[47] 
IIGT Mice Plasmid/liposome/3 times
3 days apart/7–21 days after
IIGT, the males were mated
to females 
Detection of the presence of at
least two types of the exogenous
DNA, intact and deleted form of
plasmid in F0 offspring, suggesting
degradation of the exogenous DNA
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Method Species DNA/transfection method Outcome (note) References 
IIGT Mice Plasmid/EP LacZ activity was detected in
spermatogenic cells up to 4 weeks
after IIGT 
[49] 
IIGT Mice Adenovirus/EP EP might be effective for
transfecting germ cells or somatic
cells 
[50] 
IIGT Mice Plasmid/PEI Transferred and expressed in
germ cells (especially in primary
spermatocytes); transfection into
Sertoli cells was not observed;
protein showed dynamic shifts in
spermatogenic cells at different




Plasmid/DMSO F0 offspring (mice) expressed
EGFP with an efficiency of 28.6%;
also 56.3% of rabbits born were





Naked plasmid (linearized) The gene-transfer efficiency
of G0 in larvae (9 h after
fertilization), juveniles (3 weeks
after fertilization), and 1-year-old
adults was 90%, 92.5%, and 60%,
respectively; genomic Southern
blot analysis showed that the
transgene was integrated in the
genome of the Tg abalone 
[52] 
IIGT Mice Linearized plasmid/liposome
(DOTAP)/IIGT at multi-sites/ 
after few weeks, the males
41% of F0 offspring exhibited
the presence of the transgenes
when PCR and Southern blot
[53] 
were mated hybridization were employed;
37% of F1 offspring obtained after
mating of F0 offspring with wild-
type mice were Tg 
IIGT Mice Linearized plasmid/EP Successful gene delivery to [54] 
undifferentiated spermatogonia
within the STs; about 94% of
females after mating with the
IIGT-treated males successfully
sired Tg pups 
IIGT Chickens Plasmid/cationic polymer The percentages of gene expression
reached the summit and became
[55] 
stable from day 70 to 160, being
12.7%, 12.8%, 15.9% and 19.1%,
respectively; Southern blot showed
that the transgene was inserted in
their genomic DNAs 
IIGT Chickens Plasmid for EGFP-lacZ dual
reporter expression/liposome
(Lipofectamine 2000) 
Ten days post-IIGT, fluorescent
sperms were not observed on
semen slides; however, sperms
positive for lacZ were detected;
specific amplicons of EGFP and
lacZ detectable in four of the
[56] 
six sequentially collected semen
samples; staining with monoclonal
antibodies demonstrated positive































































Gene Editing - Technologies and Applications 
Method Species DNA/transfection method Outcome (note) References 
IIGT Mice Plasmid/DMSO, DMA or
liposome (Lipofectin)/1 day
after IIGT, each male was
mated 
The presence of transgene in the [57] 
progeny (80% for PCR positive
when repeated injection was done;
50% for RT-PCR positive) in the
case of liposome was used; 55.5%
for PCR positive, but 22.3% for
RT-PCR positive in the case of
DMSO was used; RT-PCR analysis
of PCR positive animals showed
EGFP expression in blood cells;
repeated (4 times) injections





each male was mated 
38.46% of F0 positive for
transgenes in the case of PCR;
30.77% by Southern blotting;
36.36% of F1 were positive for the





angles into the testes of 7-day-
old males 
Transgene efficiencies were
11.76% (2/17), 14.29% (3/21),
and 11.11% (2/18), respectively;
semi-quantitative RT-PCR analysis
further showed that the introduced
[59] 
GFP gene was expressed in 3/9
integration mice; GFP expression
was observed in sperm from the F0
fetuses and F1 pups 
IIGT Mice Linearized plasmid/EP Electroporated testis expressed
EGFP even 80 days after IIGT;
EGFP expressing germ cells were
discernible in the STs; after mating
with the EP-based IIGT-treated
males with normal females, the
resultant Tg pups showed tissue-
specific expression of transgene 
[60] 
IIGT Mice Plasmid/liposome (PEI) Twenty days after IIGT, the
transgene-derived fluorescence was
detected in the testis and sperm;
foreign DNA was successfully
expressed in the treated mice: 4.0%
for G0 and 30.23% for F1 
[61] 
IIGT Mice Plasmid/liposome (DOTAP) The Tg positive rate in mouse
F1 offspring was 39.69%; gene
transmission beyond F2 generation;





goats Plasmid/EP Cultivation (organ culture) of STs
isolated from the IIGT-EP-treated
testis led to expression of GFP
24 h after EP; green fluorescence
was observed at best 23 days after
EP-based IIGT 
[63] 
IIGT Rats GFP-expressing plasmid/EP Possible integration of transgene
into the genome of the
spermatogonial cells; a transgenic
disease model displaying alpha
thalassemia was successfully
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Method Species DNA/transfection method Outcome (note) References 
IIGT Mice Linearized Plasmid/hypotonic
Tris-HCl solution 
Successful internalization of the
transgene in spermatogonia within
STs; such IIGT-treated males
generated Tg progeny by natural 
mating 
[65] 
IIGT Mice Plasmid/BMPs-PEI DNA complexed with BMPs-PEI
successfully reached the cytoplasm
and the nucleus of spermatogenesis
cell; the transgene was expressed in
the testes of Tg F0 mice; the ratio of
Tg F0 offspring was 88% 
[66] 
IIGT Goats Plasmid/EP Successful transfer of the transgene
into STs and testicular cells;
chromosomal integration of the
transgene and its expression in sperm;
natural mating of a pre-founder buck
produced aTg baby goat 
[67] 
STGT Mice/pigs Plasmid/liposome (obtained
from Gibco) 
In mice, 8.0–14.8% of STs expressed
the introduced LacZ gene, and
7–13% of epididymal sperm had the
foreign DNA; in pigs, foreign DNA
was also incorporated into male
germ cells, and 15.3–25.1% of the
STs containing germ cells expressed
the LacZ gene 
[68] 
STGT Rats Adenovirus Expression of the transgene in Sertoli
cells and persisted for at least 10 days 
[35] 
STGT Mice Plasmid/EP Specific lacZ expression only
in haploid spermatid cells;
spermatogenic differentiating
cells maintained the transfected
lacZ expression after more than 2
months of transfection, suggesting
that spermatogenic stem cells
and/or spermatogonia could also
incorporate foreign DNA 
[69] 
STGT Mice Plasmid/EP Transient expression of GFP
in the innermost region of the
testis uniformly, but confined to
spermatogenic cells and Sertoli 
cells within the STs; GFP was
detected in the spermatogenic
cells even 2 months after EP; no Tg 
offspring were obtained 
[70] 
STGT Mice Plasmid/EP After EP-based STGT, fluorescent
sperm were collected from the
STGT-treated STs; these fluorescent
[71] 
sperm were found to have the
ability to produce Tg offspring,
when ICSI was performed 
STGT Mice adeno-, adeno-associated-,
retro-, and lentiviral vectors 
Transduction with either adeno- or
lentiviral vectors led to reporter gene
expression for more than 2 months
after STGT; lentiviral vectors
[72] 
used to express the c-kit ligand
in Sl/Sl(d) Sertoli cells restored
spermatogenesis; lentiviral vectors
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Method Species DNA/transfection method Outcome (note) References 
STGT Mice Plasmid/EP By electrotransformation of a
complete cDNA in Sertoli cells,
defective spermatogenesis was






As early as 48–96 h post-injection,
lacZ expression was observed within
both immature and differentiated
germ cells; by 40 days post-injection,
it was restricted to the most
[74] 
immature germ cells; after mating
with females, the transgene was
transmitted to the offspring, but
remained episomal 
STGT Mice Adenovirus Strong expression in Sertoli cells
after STGT, but no expression in
germ cells 
[46] 
STGT Mice Retrovirus Transduction of spermatogonial
stem cells with an average
efficiency of 2.8%; the transgene
was transmitted stably and
expressed in the next generation 
[75] 
STGT Mice Plasmid/EP STGT was performed to examine
testis-specific gene promoter
activity; successful in vivo transient
transfection to living mouse testis
was achieved 
[76] 
STGT Mice Plasmid/EP LacZ activity was detected in
spermatogenic cells up to 8 weeks
after EP-based SMGT 
[49] 
STGT Hamsters Plasmid/EP Sixty days following gene transfer,
expression of the transgene can be
detected in epididymal sperm 
[77] 
STGT Mice Plasmid/EP The transgene products were found
on the head and mid-piece regions
of mature epididymal sperm 
[78] 
STGT Mice Plasmid/EP A fluorescent reporter protein
expressed in male germ cells 
[79] 
STGT Mice Plasmid RNAi targeting
EGFP/EP 
Sertoli cells were the main
transfected cells 
[80] 
STGT Mice Plasmid/EP STGT is useful for testing the
tissue-specific promoter activity
included in the construct in vivo 
[81] 
STGT Mice Adenovirus Sertoli cell-specific expression of GFP [82] 
STGT Mice Lentivirus All male pre-founder mice
produced Tg pups with an overall
success rate of over 60% 
[83] 
STGT Mice Lentivirus 14.3% of the lentivirus-injected
mice successfully produced Tg
pups; eight Tg founders were
obtained from the total 336 pups;
the Tg efficiency was around 2.4% 
[84] 
EpiGT Rats Plasmid/EP After 72 h, the initial segments
had intense fluorescence in the
cytoplasm of the epithelial cells 
[85] 
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Method Species DNA/transfection method Outcome (note) References 
EpiGT Mice Plasmid/lipid (FuGENE 6) Transfection was observed in
39.70% of epithelial cells after
2 days and in 31.77% after 7 days;
the presence of the transgene in
the DNA isolated from the treated
epididymides (by PCR); GFP gene
expression appeared in large areas
of the cauda epididymis even after
2 weeks post-EpiGT 
[86] 
VDGT Mice/rats Plasmid Uptake of exogenous DNA
occurred in 60–70% of the
spermatozoa after in vitro or in
vivo treatments; positive signal
was detected in the sperm nucleus
and was not affected by DNase
treatment 
[87] 
VDGT Mice Mixture of linearized and
circular plasmids 
From 53 newborns, four were
found positive by PCR for the
GFP gene; some tissues showed




Maximum of 6.8% in the epithelial
cells of the vas (for lacZ staining);
13.3% after employing the GFP
gene construction; expression of
the GFP gene appeared from 1 week
up to 3 months following injection 
[89] 
1TMGT can be defined as a method for in vivo gene delivery towards male reproductive systems (testis, epididymis, 
and vas deferens) and includes intratesticular injection-based gene transfer (IIGT), seminiferous tubule-mediated 
gene transfer (STGT), epididymis-mediated gene transfer (EpiGT), and vas deferens-mediated gene transfer 
(VDGT). 
Abbreviations: BMPs, bacterial magnetic particles; DMSO, dimethyl sulfoxide; DOTAP, N-[1-(2,3-Dioleoyloxy) 
propyl]-N,N,N-trimethylammonium methyl sulfate; DMA, N,N-dimethylacetamide; EP, electroporation; GFP, green 
fluorescent protein; IVF, in vitro fertilization; PEI, polyethylenimine; STs, seminiferous tubules; Tg, transgenic; TB, 
trypan blue. 
Table 1.
Summary of testis-mediated gene transfer (TMGT)1-related studies. 
In the following sections, the TMGT-related experiments will be mentioned in
more detail. 
2. Historical background of TMGT-related experiments 
2.1 IIGT-related experiments 
Between 1994 and 2006, over 20 reports on IIGT-related experiments were
reported using various animal models such as mice, rats, hamsters, rabbits, boar, 
goats, chicks, fishes, and shellfishes [29, 31–41, 43–53, 68]. The DNA used were
mainly plasmid DNA that had been mixed with calcium phosphate, liposomes/ 
lipids, polyethylenimine (PEI), or DMSO, all of which were intended to facilitate
uptake of DNA by sperm or spermatogenic cells [29, 31–34, 37–40, 44, 47, 48, 51, 
68]. The method to use in vivo EP towards the entire testis after IITG with naked 
plasmid DNA was also employed [36, 41, 45, 49]. Furthermore, adenoviral vectors
were introduced by IIGT [35, 43, 46, 50]. 
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i. Transgene expression in a testis after IIGT: IIGT using an adenoviral vector
resulted in preferential transgene expression in Leydig cells [46]. Mogas
et al. [43] reported that transgene-derived protein is mainly present in the
interstitial tissue of a testis, and in STs 7–16 days after inoculation. Li et al. [51]
demonstrated that plasmid DNA mixed with PEI can be transferred within STs
after IIGT and expressed in primary spermatocytes, but not Sertoli cells. 
ii. Detection of transgenes and expressed products on the epididymal or
ejaculated sperm: According to Yonezawa et al. [40], foreign DNA encapsulated
by DMRIE-C and SuperFect can be detected by PCR in the cauda epididymis-
derived sperm isolated 1, 4, and 14 days after IIGT. The exogenous DNA was also
detectable in the ejaculated sperm collected from the uterine horn of the females
in the morning after mating with the IIGT-treated males [31, 38]. 
iii. Transgene expression in the F0 offspring obtained after mating with the
IIGT-treated males: PCR analysis revealed that detection of the transgenes in
the mid-gestational fetuses was found at frequencies ranging about 50–85% [39].
However, the copy number of the transgenes in those fetal DNA are estimated
to be <1 copy per diploid cell [32]. PCR/slot blot analyses revealed that 41% of
F0 offspring had the transgenes [53]. Ogawa et al. [34] reported that 80% of
blastocysts exhibited the transgene-derived lacZ gene coding for β-galactosidase,
one of the key enzymes consisting of lactose operon. Sato et al. [39] reported that
lacZ expression was evident in most (72%) of the blastocysts, but neither expres-
sion of the LacZ gene nor its mRNA was found in the mid-gestational fetuses.
More than 80% of morulae expressed EGFP, but the ratio of animals carrying the
foreign DNA decreased as they developed, and only some of the progeny were
foreign DNA-positive with high incidence of mosaicism [40]. 
iv. Transgene transmission to the next generation: Gene transmission to F1 
offspring was at frequencies ranging about 16–23%, but when F2 offspring 
was obtained from mating normal female with F1 male offspring, about 94% 
of F2 offspring had the transgenes, suggesting that the introduced DNA 
was chimeric in these F0 mouse testes [38]. On the contrary, He et al. [53] 
demonstrated that the transgene transmission rate from F0 to F1 generation
was 37%, suggesting that the transgene transmission rate was similar to the
Mendelian law of inheritance. 
In 2007 and onward, attempts to improve IIGT systems were made by several 
laboratories to enhance the gene delivery efficiency [54–67]. In the following 
sections, we will describe several examples [(v) to (x)] about the improvement
of IIGT, in vitro assessment for gene expression after IIGT or possible mechanism
underlying IIGT. 
v. IIGT at a young stage: In mammalian testis, spermatogenesis occurs in the
STs of a testis (Figure 3d). In the ST, there are spermatogenic cells called
spermatogonia (spermatogonial cells) that can be further matured into
spermatocytes and spermatids. Spermatogonia are largely divided into two
types, type A and type B cells. The former undergoes active mitosis and divide
to produce type B cells. The type B cells divide to give rise to spermatocytes
and spermatids, which move towards the lumen of the ST as they mature.
According to Hui-ming et al. [59], type A spermatogonia first appear between
3 and 7 days postnatally in mice and are the only immortalized diploid cells.
They considered that if these type A spermatogonia are stably transfected with
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sperm leading to production of Tg mice through natural fertilization. Based
on this hypothesis, they performed IIGT using GFP-expressing plasmid DNA
encapsulated by the ExGen500 transfection reagent on 7-day old male ICR
mice. When these treated mice reached different stages of sexual maturity (6,
12, and 24 weeks of age), they were mated with normal females. The resulting
pups were identified as Tg, with efficiencies of 11–14%. They observed GFP
expression in sperm cells isolated from F0 and F1 pups. They referred to this
technology as “type A spermatogonia-mediated gene transfer” (TASMGT). 
vi. EP-based IIGT: Majumdar’s group developed a method for generating Tg
mice by directly injecting the desired gene into the testis followed by in vivo
EP [54]. In this method, one of the testis was surgically exposed for DNA
injection (Figure 1a) and the other contra-lateral testis was removed. An
improved version of this EP-based IIGT was provided by Usmani et al. [60],
who introduced the transgenes to both testes of mice directly from the outside
(Figure 3a), prior to in vivo EP. They employed a two-step EP in which four
60 V electric pulses (50 ms each with an inter-pulse interval of 1 s) in one
direction (forward direction) (Figure 3b) and four more pulses after chang-
ing the sides of the electrodes (reverse direction) (Figure 3c). The EP-based
IIGT-treated testis expressed EGFP from the introduced transgenes even at
80 days of age. Furthermore, fluorescent germ cells were discernible in the STs
of those mice (Figure 3d). F1 offspring that were generated after mating the
IIGT-EP-treated males with normal females showed tissue-specific expression
of transgenes. This improved procedure is based on non-surgical gene delivery
using a two-step EP, which appears to be a user-friendly technique for a person
who is less experienced in performing surgery. 
vii. In vitro EP-based IIGT: It is difficult to apply IIGT in the testis of larger
animals such as goats, because the size of the testis is much bigger than that of
smaller animals such as mice and rats. Raina et al. [63] hypothesized that IIGT
may be possible when in vitro gene delivery is performed towards the testis
dissected from goats. They slowly injected GFP-expressing plasmid DNA into
the interstitial space at eight different sites of the isolated testis using a 1-mL
syringe (Figure 4a). Then, the testis was subjected to in vitro EP using a pair of
tweezer-type electrodes (Figure 4b). After that, ST was partially dissociated
and placed under in vitro cultivation for checking GFP expression at regular
intervals (Figure 4c, d). A strong green fluorescence signal was observed 24 h
after EP and its expression was continuously observed for as long as 23 days
post-EP. The authors mention that the results of this study cannot be applied
straightforwardly for in vivo studies, but the in vitro transfection of ST using
EP will provide valuable baseline information, prior to IIGT in vivo. 
viii.IIGT using a simple hypotonic solution: Majumdar’s group have developed a 
method to generateTg mice by directly injecting the desired gene in the testis 
followed by in vivo EP, as mentioned above [54, 60]. This technique is less com-
plicated for small animal like mice but appears to not be feasible for transgenesis 
in large animals, because these animals have larger testes and greater scrotal
thickness, to which it is difficult to standardize voltage parameters. To overcome 
this difficulty, they developed an alternative technique for making Tg mice by 
hypotonic shocking male germ cells for gene delivery. According to Usmani et al.
[65], treatment with hypotonicTris-HCl solution reduced osmolarity and led to 
hypotonic-swelling of germ cells. The hypotonic-swelling eventually killed the 
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Figure 3.
EP-based IIGT in mice. a-c. Schematic illustration for EP-based IIGT. After IIGT towards both testes (a), they 
are held by a pair of tweezer-type electrodes and then subjected to the first in vivo EP (b). The second EP was 
next performed by changing the direction of electric pulse (c). (d) Structure of a ST. The colored spermatogenic 
cells and Sertoli cells indicate cells successfully transfected by the exogenous DNA that have been instilled within 
a lumen of ST. 
Figure 4.
In vitro EP-based IIGT in goats. The isolated goat testis is subjected to IIGT with a total of eight repeated 
injections from different directions (a). Then, the entire testis is hold by a pair of electrodes prior to EP (b). 
After that, the EP-treated STs are partially dissected and subjected to in vitro cultivation (c). By this, the 
transgene expression on the spermatogenic cells of STs can be monitored continuously (d). 
such as nucleosides inside the cell. The authors hypothesized that a hypotonicTris-
HCl solution at a certain hypotonic concentration might allow the germ cells to 
internalize the surrounding solutes like DNA in vivo without being killed and the 
sperm produced from transfected germ cells may carry a desired DNA fragment 
(transgene) to generateTg animals. Usmani et al. [65] suspended the linearized
plasmid DNA (transgenes) in hypotonic Tris-HCl solution (pH 7.0) and simply
performed IIGT to internalize the injected transgenes in the genome of sper-
matogonia residing at basal compartment of tubules. As a result, such males
successfully generated Tg progeny by natural mating. This technique is easy and
simple and does not require expensive apparatuses like electroporators. Usmani
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own Tg animals, instead of outsourcing, and would drastically minimize the
time required for studies on functional genomics. 
ix. IIGT using nanoparticles: It has previously been reported that nanoparticles
such as magnetic nanoparticles, mesoporous silica nanoparticles, and hal-
loysite clay nanoparticle can be used as a vehicle for delivering exogenous
DNA to sperm of various animals, such as boar and bovine [30, 94–96].
However, these early reports are confined to in vitro events. Wang et al. [97]
applied this technology to IIGT using bacterial magnetic particles (BMPs)/ 
PEI complex-conjugated foreign DNAs (BMP-PEI-DNA complex). According
to Wang et al. [97], BMPs help to reduce the toxicity of the PEI, an efficient
gene transfer agent, and assist gene delivery in vivo. After performing IIGT in
mice, the testis was returned to the original position, and a neodymium-iron-
boron magnet with an intensity of 600 milliteslas (mT) was placed onto the
surface of the abdomen to facilitate gene delivery towards the spermatogenic
cells. The authors report that this procedure is not harmful to the function-
ing of the testis. They reported that the clusters of BMP-PEI-DNA complex
successfully reached the cytoplasm and the nucleus of spermatogenic cell and
expressed in the testes of F0 mice. The resulting F0 mice could transmit the
introduced transgene to the offspring with efficiencies of 88%. 
x. Possible mechanism for IIGT-mediated gene delivery to sperm: When
intratesticular injection of a DNA-containing solution into the interstitial 
space of a testis is performed, the fate of the injected solution is largely
divided into two routes. This was first assessed by Sato et al. [42] who
employed trypan blue (TB) as dye to visualize the transferring solution. One
route is when a solution is transferred to the epididymal ducts, and the other
route is when a solution is transferred to the lumen of the STs (Figure 5). 
After the intratesticular injection of 30 μL TB, the dye was rapidly trans-
ferred via rete testis to the proximal segment of caput epididymis [42]. One
day after the injection, the dye was observed in the middle segment of caput
epididymis. This was also confirmed by a previous observation using PCR 
analysis, which revealed the presence of the exogenous DNA in the sperma-
tozoa isolated from caput epididymis [31]. Furthermore, the exogenous DNA 
can be detected in the ejaculated sperm collected from the uterine horn 1 
day after mating with females [31]. Thus, it is reasonable to consider that the
exogenous DNA injected into the interstitial space of a testis is rapidly trans-
ferred to the epididymal ducts and taken up by epididymal sperm in situ. 
Only a minor portion of the solution injected into the interstitial space of a testis
is transferred inside the STs. This may be elicited by mechanical shearing of STs
upon insertion of a needle or glass capillary. To increase the transfection efficiency
in the spermatogenic cells existing within STs, repeated needle insertions (over at
least three times from different sites) have been employed by some research groups
[34, 46, 53, 59, 63]. At present, it remains unknown how many STs are indeed 
transfected by this treatment. Usmani et al. [65] reported that spermatogenic cells, 
including spermatogonia present within STs, are transfected after IIGT and subse-
quent in vivo EP using fluorescent marker genes. 
2.2 STGT-related experiments 
ST is a tubular structure packed in a testis, which contains spermatogenic cells,




























   
 
  
Gene Editing - Technologies and Applications 
Figure 5.
Possible mechanism of how the exogenous DNA introduced into the interstitial space of a testis is transmitted to 
epididymal sperm or to spermatogenic cells within a ST. 
(spermatocytes and spermatids), and Sertoli cells, which support the prolifera-
tion and differentiation of spermatogonia (Figure 3d). If the exogenous DNA is
introduced within a lumen of the ST, it is possible to transfect those spermato-
genic cells, from which transfected spermatozoa are transported via epididymal
ducts and finally ejaculated upon mating with estrous females. As a result, the
introduced exogenous DNA will be transmitted to oocytes via fertilization with
the transfected sperm. 
To our knowledge, STGT was first performed in 1997 by two groups: Blanchard and
Boekelheide [35], with rats using adenoviral vector, and Kim et al. [68], with mouse
and pigs using liposomally encapsulated plasmid DNA. The aim of the former group
was to study transgene expression in the adult rat testis in vivo. They demonstrated that
there was transgene expression in Sertoli cells and principal cells of the epididymis, and
expression persisted for at least 10 days. The latter group demonstrated that in mice,
8.0–14.8% of STs expressed the introduced transgene, as evaluated by histochemical
staining for the lacZ gene, and 7–13% of epididymal sperm had the exogenous DNA, as
evaluated by PCR analysis. In pigs, 15–25% of the STs contained lacZ-positive germ cells.
They suggested that STGT can be used as a powerful tool for producing Tg livestock. 
In 1998, Yamazaki et al. [69] employed STGT for examining transcriptional
regulatory elements of spermatogenic specific genes. After injecting DNA into
STs, subsequent in vivo EP was used to enhance DNA uptake by spermatogenic
cells. Based on these experiments, they suggested that spermatogenic stem cells
and/or spermatogonia can incorporate foreign DNA, and that the transgene could
be transmitted to the progenitor cells derived from a transfected proliferating
germ cell. Later, the same group [70] examined the possibility to create Tg off-
spring using STGT coupled with in vivo EP (EP-based STGT). Although long-
lasting transgene expression could be detected in the spermatogenic cells even 2
months after EP, no Tg offspring were obtained after natural mating with normal
adult females. 
Huang et al. [71] used the EP-based STGT towards an entire mouse testis after
intratubular injection of plasmid DNA that coded for fluorescent genes. To trace the
fate of transfected spermatogenic cells, they obtained fluorescent sperm by fluores-
cence activated cell sorting (FACS), and performed ICSI to obtain their offspring. 
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claim that this is the first report of gene transfer into germ cells and subsequent
production of Tg offspring. 
STGT appears to be the direct approach to transfect spermatogenic cells in
situ, but most experiments [46, 49, 51, 72–84] have been confined to successful
transfection of spermatogenic cells and Sertoli cells for rescuing damaged/inactive
Sertoli cells, in vivo testing of efficiency of RNA interference (RNAi), or estab-
lishment of an in vivo assay system to evaluate the promoter activity of the gene
of interest. There have been no trials to create Tg offspring through STGT. Only
some groups have tried to test the possibility of creating Tg animals by STGT. For
example, Celebi et al. [74] performed STGT using circular plasmid carrying the
lacZ reporter gene mixed with noncommercial cationic lipids. These injected males
were mated with wild-type females and the progeny were analyzed by PCR and
Southern blot assay. They demonstrated that the transgenes were transmitted to
the offspring, but remained episomal, since it was found in the tail of the young
animals and was lost at adulthood. Therefore, the plasmid seemed to be lost during
the numerous germ cell divisions. This plasmid stayed in some tissues, such as
in the skeletal and cardiac muscles. No integrative forms have yet been found with
the use of circular DNA. Kanatsu-Shinohara et al. [75] described a novel approach
for producing Tg animals by transducing spermatogonial stem cells in vivo using a
retroviral vector by STGT. When these injected males were mated with wild-type
females, Tg offspring were obtained with an efficiency of 2.8%. The transgene
was transmitted stably and expressed in the next generation. The authors, thus,
concluded that this technique will be useful as an alternative to the pre-exiting
microinjection-based transgenesis, as well as provide a means for analyzing the
self-renewal and differentiation processes of spermatogonial stem cells in vivo. 
Sehgal et al. [83] described a technique for the generation of Tg mice by infection
of spermatogonial stem cells with recombinant lentiviruses expressing EGFP with
a high rate of success. When the infected males were mated to normal females, over
60% of the delivered pups were found to be Tg. Li et al. [84] employed methods
similar to those of Kanatsu-Shinohara et al. [75] and Sehgal et al. [83] and reported
that the Tg efficiency is around 2.4%, which is similar to the previous report of
Kanatsu-Shinohara et al. [75]. 
2.3 EpiGT-related experiments 
Epididymal sperm present on the ducts of caput and cauda epididymides
and epididymal epithelial cells can be targeted for transfection by the exogenous
DNA. Kirby et al. [85] performed intraluminal injections (2–5 μL) of plasmid DNA 
into the lumen of an initial segment tubule of caput epididymis (Figure 2b), and 
subsequent in vivo EP towards the injected portion to examine the function of
epididymal epithelial cells, which are thought to play critical role in sperm matura-
tion during transport through epididymides. They concluded that this procedure
is useful for elucidating the activity of promoter elements included in the injected 
plasmid that may not be identified when traditional in vitro methods are used. 
Esponda and Carballada [86] injected plasmid DNA mixed with the lipid FuGENE6 
into the lumen of mouse cauda epididymis (Figure 2c). Successful transfection was
observed in about 40% of cells after 2 days and in about 32% after 7 days, and then
diminished progressively over time. Gene expression continued up to 15 days after
gene injection and occupied about 22% of the area of the tubules. They concluded 
that intraluminal injections of exogenous DNA are effective for the study of
epididymal physiology or to change the fertilizing ability of sperm. These studies
are not aimed to create Tg animals, but they hold a potential to transfect epididymal 
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2.4 VDGT-related experiments 
In 1998, the Esponda’s group [87] first attempted to examine whether exog-
enous plasmid DNA introduced into the lumen of the proximal region of the vas
deferens could be taken up by mouse and rat sperm (Figure 2d). They demon-
strated that 60–70% of sperm recovered 6 h after DNA injection had positive
signal for successful transfection in their sperm nucleus, which was not affected
by DNase treatment. This was also confirmed by PCR and slot blot analyses.
They concluded that sperm within the vas deferens had the ability to incorporate
exogenous DNA, which can be transferred to their nuclei, and vas deferens secre-
tions do not block these capacities. In 2000, the same group [88] showed that this
VDGT is useful for production of Tg mice. They injected plasmid DNA encoding
GFP into the lumen of mouse vas deferens. The night after injections, males were
mated with normal estrous females, and the offspring were analyzed. About 8%
(4/53) of the newborns delivered expressed the GFP gene. They concluded that
VDGT is a simple alternative to the pre-existing microinjection-based production
of Tg animals and can be used for species in which the microinjection procedure
is not feasible. This technology was later found to also be useful for transfection
of epithelial cells of the vas deferens using a direct injection of DNA-liposome
complexes, which could modify vas fluid contents [89]. 
3. Historical background of SMGT-based AI 
As mentioned previously, AI of transfected sperm with exogenous DNA through
SMGT is a highly convenient route for producing Tg animals. To our knowledge, 
Sperandio et al. [98] was the first to demonstrate its usefulness in domestic animals, 
such as bovine and swine. They performed AI towards ten sows with boar sperm
cells that had been preincubated with plasmid DNA and obtained 82 offspring. 
Southern blot analysis of the DNA extracted from the animal tails showed that five
animals were Tg and contained sequences complementary to the exogenous plasmid 
DNA that appeared to be rearranged compared to the original plasmid. From this
study, it was suggested that SMGT-AI can be successfully adapted for the genera-
tion of Tg livestock. Yonezawa et al. [99] tested whether liposome-peptide (derived 
from human protamine)-DNA complex (LPD), a new reagent known to stabilize
transfection in cultured cells, was useful to increase the efficiency of SMGT. They
performed AI using rat epididymal sperm that had been incubated in a solution
containing GFP expressing plasmid DNA and LPD complex. Expression of GFP
was detectable in the morulae isolated from the treated animals. Furthermore, the
AI-treated animals produced pups carrying foreign DNA. 
This SMGT-AI is applicable to avian species. Yang et al. [100] performed AI 
using freshly-ejaculated chicken sperm that had been incubated in the presence of
plasmid DNA and liposome, and found that about 4% (2/53) newly hatched chicks
was identified as Tg. Harel-Markowits et al. [101] employed restriction enzyme-
mediated insertion (REMI) to increase the efficacy of the transfection towards the
isolated chicken sperm. REMI was used to insert exogenous DNA linearized with
a restriction enzyme that cuts the genomic DNA at sites that enable the exogenous
DNA to integrate via its matching cohesive ends [102, 103]. Following insemination
with sperm transfected with linearized DNA, restriction enzyme, and liposome, 
they obtained Tg offspring. Furthermore, when chicken sperm are incubated in a
solution containing plasmid DNA and DMSO or N,N-dimethylacetamide (DMAc) 
and subsequently subjected to AI, the resultant newborn chicks have the trans-
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DMAc-treated group) [104]. However, Chaparian et al. [105] recently reported that
they were unable to create Tg chicks by SMGT-AI. 
4. Exosomes as a possible carrier to deliver genetic materials to sperm 
Exosomes, membrane-enclosed sub-cellular microvesicles shed from most cell
types, are present in a wide variety of body fluids [106]. Recently, it was found that
they can mediate various effects on the behavior of recipient cells, since they contain
cytokines, growth factors, and membrane proteins [107]. Furthermore, they contain
a substantial amount of small and functional RNA molecules, called microRNAs
(<100 nucleotides in length) [108], which could potentially control gene expression
of various endogenous genes. It has recently been shown that these exosomes are (1)
found in human semen [109], (2) involved in sperm maturation process during the
transit along the male epididymal tracts [110], (3) accumulated in mature spermato-
zoa nuclei [111], and (4) delivered to oocytes through fertilization [112]. 
Notably, there are some reports describing non-Mendelian germline-inde-
pendent inheritance of phenotypes in the absence of any classically identifiable
mutation or predisposing genetic lesion in the genome of individuals who develop
the disease [113–115]. For example, Cossetti et al. [116] performed subcutaneous
inoculation of EGFP-expressing human melanoma cells into an immunocompro-
mised mouse, from which EGFP RNA was released from the grafted melanoma
cells, delivered to the bloodstream, and finally brought to sperm. When epididymal 
sperm isolated from these tumor-bearing males were examined carefully, the EGFP
RNA was found to be tightly associated with the extracellular fraction of these
mature sperm. They termed this phenomenon “soma-to-germ line transmission of
information,” and thought that exosomes may be involved in this phenomenon as
the carrier to deliver EGFP RNA. The findings of Cossetti et al. [116] appear to be
well correlated with those obtained from the TMGT-related experiments done at
earlier stages of IIGT development, which include (1) non-Mendelian transmission
of the exogenous DNA in the offspring obtained [33], (2) extreme low copy number
of the exogenous DNA (<1 copy per diploid cell) transmitted to these offspring 
[32], (3) mosaic expression of the exogenous DNA in the offspring (blastocysts) 
obtained [33, 40], and (4) reduction in the number of offspring carrying the
exogenous DNA during development [40]. As mentioned in Section 2.1 (x), parts of
a solution introduced into the interstitial space of a testis is transferred to the excur-
rent ducts of epididymides, and the exogenous DNA may be taken up by the extra-
cellular fraction of epididymal sperm, possibly through exosomes. We detected the
presence of exogenous DNA in the DNase I-treated epididymal sperm, which have
been isolated from the IIGT-treated males [42]. This may be due to the fact that
exosomes can protect its exogenous DNA against DNase I-mediated digestion. 
Notably, in their review article, Jiang and Gao [117] demonstrated that exo-
somes can be used as naturally occurring cell-to-cell transporters or as novel bio-
carriers for gene and drug delivery. These exosomes are naturally secreted by the
cells and pass through additional biological barriers. They are more biocompatible
and biodegradable and can avoid immune response which is most likely due to
the surface expression of the complement regulatory proteins, such as CD55 and
CD59. For these natural characteristics, exosomes are being extensively explored
as gene delivery vehicles. For example, in 2011, Alvarez-Erviti et al. [118] first
demonstrated that exosomes are useful for delivering short interfering (si)RNA to
the mouse brain. They engineered dendritic cells to express lysosome-associated
membrane protein 2 (Lamp2) isoform (Lamp2b), an exosomal membrane protein
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the gene-engineered dendritic cells and loaded with siRNA using electropora-
tion and were administered intravenously to mice. As a result, the targeting
peptide was shown to be successfully delivered to the brain. The concomitantly
delivered siRNA caused reduced expression of a target protein associated with the
pathogenesis of Alzheimer’s disease. Furthermore, Lin et al. [119] proposed that
exosomes can be a good carrier to introduce various cargoes, including plasmid
DNA, into a cell. They prepared a mixture composed of purified exosomes
isolated from HEK293FT cell line, pEGFP-C1 plasmid DNA, and Lipofectamine
2000 liposomes in vitro. During the incubation at 37°C for 12 h, exomes and
liposomes are fused together and the exogenous plasmid DNA becomes incorpo-
rated into exosome-liposome hybrid nanoparticles. Transfecting mesenchymal
stem cells (MSCs), which cannot be transfected by the liposome alone, with this
complex resulted in successful generation of fluorescent cells when evaluated by
FACS. Now, an exosome-based transfection kit, possibly based on this principle, is
commercially available: Exo-Fect Exosome Transfection Kit (System Biosciences).
We confirmed the usefulness of this kit by in vivo transfecting oviductal epithelial
cells through intraoviductal instillation of a solution prepared using this kit.
Some oviductal epithelial cells were found to be fluorescent after transfection
with a plasmid expressing GFP (unpublished results). Thus, it may be possible
to transfect isolated sperm by incubating plasmid DNA and exosome/liposome
hybrid vesicles provided from the Exo-Fect Exosome Transfection Kit, prior to AI
as mentioned below. 
5. Genome-editing sperm 
Gene modification based on recently developed techniques such as zinc-finger
nucleases (ZFNs), TAL effector nucleases (TALENs), and clustered regularly
interspersed short palindromic repeats/CRISPR-associated protein 9 (CRISPR/ 
Cas9) are now recognized as a revolutionary genetic engineering tool in vitro and
in vivo [120–124]. Three types of endonucleases from ZFNs, TALENs, and CRISPR/ 
Cas9 have been developed to promote precise genome editing at a target gene. All
these enzymes have a DNA-binding ability and an ability to elicit double-strand
DNA break (DSB) at a target genomic locus. Subsequently, in the absence of a
homologous template to repair, nonhomologous end joining (NHEJ) occurs and
causes small insertions or deletions (termed “indels”). In the presence of a tem-
plate donor DNA, site-specific recombination through homology-directed repair
(HDR) occurs. Generally, the frequency of NHEJ is thought to be higher than that
of HDR in most of the cell types [125]. Table 2 shows comparison among these
three technologies. 
ZFNs are the first engineered endonucleases [127] that combine the DNA
recognition ability of zinc-finger protein (called zinc-finger motifs) and
restriction enzyme Fok I to introduce DSB [120–124]. In 2005, Urnov et al.
[128] first demonstrated that ZFNs are effective as a genome editing system in
the human cells. 
TALENs are similar to ZFNs and require a string of TALEN motif (consisting of
a series of 33–35 amino acid repeats) to bind to the specific sequence of a target gene
and Fok I enzyme to introduce DSB [120–124]. TALENs provide more flexibility
to the target sequences since ZFNs are known to be more active towards GC-rich
region, whereas TALENs can be assembled to the target AT-rich regions [120–124]. 
Since both ZFNs and TALENs require assembling of an array to build each set,
which is a complex and time-consuming process [124], CRISPR/Cas9 has become the
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TALE and Fok I fusion
protein 
TALE and Fok I fusion protein Cas9 protein
and sgRNA 
Design Easy Easy Very easy 
Construction Easy Easy Very easy 
Efficiency High High High 
Off-target rate Low 
1Based on Chen and Gao [126]. 
High High 
Table 2.
Comparison of ZFN, TALEN, and CRISPR/Cas9-mediated genome editing systems1. 
the Cas9 nuclease and a single-guide RNA (sgRNA), which is a short sequence to
guide the Cas9 protein to a target site. More importantly, these events are performed
by transient interaction of Cas9 and sgRNA, whereby chromosomal integration of the
CRISPR components is not a prerequisite [129]. There is a concern of off-target cleav-
age activity from the endonuclease from CRISPR/Cas9 because the system requires
recognition of only 20 bp target sequence and allows up to 5 bp mismatches for the
formation of DSB [124]. Several strategies for minimizing the off-target cleavage have
been employed including use of double nickase mutant form of Cas9, which induces
a single-strand break instead of DSB [130]; use of Cas9-sgRNA ribonucleoprotein
(RNP) complex, whose half-life is shorter than that the time in which plasmid or viral
nucleic acid is transcribed [131]; or use of fusions of catalytically inactive Cas9 with
Fok I nuclease domain (fCas9) to improve the DNA cleavage specificity [132]. 
In the case of producing GM animals using SMGT or TMGT, it is better for the
exogenous DNA (transgenes) to be integrated into the chromosomes of sperm. This
event appears to occur more frequently in immature sperm cells present in the ST
of a testis than in the mature epididymal sperm because the chromosomal DNA in
the latter cells is tightly packed in the head region of a sperm. In this context, STGT
is a preferable system to create GM animals because it is targeted to transfection
of spermatogenic cells present within the STs. However, it takes about 4 weeks
for mature sperm to reach the epididymal portion for fertilization. If a researcher
wants to generate GM animals within a short period of time, direct transfection
of mature sperm present in epididymides or vas deferens is recommended. In this
case, as mentioned above, the introduced exogenous DNA may be associated to
the extracellular fraction of a sperm, as episomal DNA. Notably, CRISPR/Cas9-
based genome editing does not always require chromosomal integration of its
components; it can be performed by transient expression of their components after
transfection [129]. In this sense, an attempt to transfect mature sperm would be a
useful alternative for GM animal production. 
6. Proposal of new experimental systems for simple creation of 
genome-edited animals using in vivo or in vitro transfected sperm 
In the following section, we propose two experimental plans to create genome-
edited animals using VDGT or AI-based systems, all of which are simpler and more
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6.1 VDGT-based genome editing 
As previously described in Section 2.4, VDGT enables transfer of exogenous DNA
to oocytes via fertilization by mature sperm transfected within vas deferens [87, 88].
Injecting a solution containing genome editing components (e.g., sgRNA + DNA/ 
mRNA/protein for Cas9) into the lumen of vas deferens of anesthetized males and
subsequent mating between the VDGT-treated males and normal estrous females the
day (night) after the surgery may result in production of genome-edited offspring. 
In Figure 6a–c, experiments obtained after TB injection into the lumen of mouse
vas deferens is shown (unpublished results). Under anesthesia, cauda epididymis
and vas deferens were pulled out and a small slit was made at the proximal region of
vas deferens using micro scissors (Figure 6a). Then, a glass micropipette containing
TB was inserted into the lumen of vas deferens under observation using a dissecting
microscope and about 15 μL of the solution is slowly injected (Figure 6b). It is easily
discernible that the injected TB still remains within the proximal portion of vas
deferens immediately after the injection (arrows in Figure 6c). However, the
injected TB moved to the distal portion of vas deferens the next day (arrow in
Figure 6d). Thus, to produce genome-edited animals by VDGT, a solution contain-
ing CRISPR/Cas9 components (sgRNA + DNA/mRNA/protein for Cas9), gene
delivery enhancing reagents (such as DMSO, liposomes, microparticles, etc.) and
fluorescent marker expression plasmid DNA has to be prepared first (Figure 6e).
Figure 6.
Procedure for VDGT-based genome editing. (a–d) Experimental procedure of VDGT when TB as a visible
marker is injected into the lumen of vas deferens. Under anesthesia, a small slit is made at the proximal region of
vas deferens using micro scissors (a). Then, a glass micropipette is inserted into the lumen of vas deferens under
observation using a dissecting microscope and the solution is slowly injected (b). After TB injection, the injected
TB still remains within the proximal portion of vas deferens (arrows in c). One day after VDGT, the injected TB
moves to the distal portion of vas deferens (arrow in d), showing the flow of the injected substance. e. Experimental
procedure of VDGT when genome-editing components are injected into the lumen of vas deferens. First, a solution
containing CRISPR/Cas9 components, gene delivery enhancing reagents (such as DMSO, liposomes, microparticles,
etc.), and fluorescent marker expression plasmid DNA is prepared in a tube. Then, about 15 μL of this solution
is immediately injected into the lumen of vas deferens. On the night following the VDGT or the next day, the
VDGT-treated males are mated to normal estrous females. Later, cleavage stage embryos are collected to examine
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After short incubation period, this solution is injected into the lumen of vas defer-
ens. Then, the VDGT-treated males are mated to normal estrous females on the day
(night) or next day. Later, cleavage stage embryos were collected from the VDGT-
treated females to examine the presence and expression of the transgene (plasmid)
(Figure 6e, bottom) and occurrence of mutations in a target locus. In some cases,
the SMGT-AI-treated females were allowed to deliver their pups to see whether
genome editing is induced in their chromosomes. 
6.2 SMGT-AI-based genome editing 
AI is one of the assisted reproduction technologies that is based on the introduc-
tion of isolated sperm into the female reproductive tracts, such as uterine horn or
oviductal lumen, to in vivo fertilize ovulated oocytes. As previously described in
Section 3, isolated sperm are incubated in a solution containing exogenous DNA 
and gene delivery enhancing reagents such as DMSO, liposomes, and micropar-
ticles, for a short period (SMGT), and then the transfected sperm are subjected to
AI, called “SMGT-based AI” (SMGT-AI). During this process, the exogenous DNA 
should be transmitted to oocytes via fertilization resulting in Tg embryos. 
We previously reported that transfer of sperm into a space near the infun-
dibulum between the ovary and ovarian bursa enables in vivo fertilization of
ovulated oocytes in the ampulla region of the oviduct [133, 134]. In more detail,
2 μL of fresh epididymal B6C3F1 (F1 hybrid mice between C57BL/6 and C3H)
sperm (containing 2 x 105 spermatozoa) were intrabursally injected 7 h after
human chorionic gonadotropin (hCG) administration to B6C3F1 females that
had been administrated with pregnant mare serum gonadotropin (PMSG) 48 h
before. At 1.7 days after AI, normal cleaving embryos were recovered at rates of
40–100%. We called this AI technology “intrabursal transfer of sperm” (ITS)
[133]. In Figure 7a, the ITS procedure is schematically illustrated. In Figure 7b
and c, photographs before (b) and after (c) ITS are shown by using TB as a dye to
visualize the process of AI. It is clear that the injected solution is present between
the ovary and ovarian bursa (arrow in Figure 7c). In Figure 7d, an example for
SGMT-AI-mediated genome editing in embryos is schematically shown. First,
sperm isolated from the vas deferens are treated with CRISPR/Cas9 components
(sgRNA + DNA/mRNA/protein for Cas9), gene delivery enhancing reagents (such
as DMSO, liposomes, microparticles, etc.), and fluorescent marker expression
plasmid DNA for a short period. Then, the solution containing the transfected
sperm is subjected to AI towards females 7 h after hCG administration. The next
day, 2-cell embryos are collected from the AI-treated females to examine the pres-
ence and expression of the transgene (plasmid) and occurrence of mutations in
a target locus. In some cases, the SMGT-AI-treated females are allowed to deliver
their pups to see whether genome editing is induced in their chromosomes.
Notably, the selection of a successfully genome-edited sperm prior to AI may
accelerate the production efficiency of genome edited offspring, although the
practical approach for this remains unknown at present. Therefore, the success or
failure of genome editing performed in this system may depend on the molecular
analysis of the offspring (e.g. blastocysts or fetuses) generated after AI of the
SMGT-treated sperm. 
7. Conclusion 
TMGT, based on direct in vivo gene delivery towards interstitial space of a testis, 
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Figure 7.
Procedure for SMGT-AI-based genome editing. (a) ITS procedure schematic. (b, c) Photographs during 
before (b) and after (c) ITS, which is shown by intrabursal injection of TB. Note the presence of TB between 
the ovary and ovarian bursa (arrow in c). (d) Experimental procedure of SMGT-AI when genome-editing 
components are injected between the ovary and ovarian bursa. First, sperm isolated from the vas deferens 
are incubated in a solution containing CRISPR/Cas9 components, gene delivery enhancing reagents (such 
as DMSO, liposomes, microparticles, etc.) and fluorescent marker expression plasmid DNA for a short 
period. Then, the solution containing the transfected sperm is subjected to AI towards females 7 h after hCG 
administration. Later, cleavage stage embryos are collected to examine the presence/expression of the transgene 
(plasmid), as well as possible mutations in a target locus. 
intensive and less time consuming for the production of GM animals. This testicular
route is also ethically superior since fewer mice are required than existing alterna-
tive methods of transgenesis. The TMGT-treated males can be used to mate with
estrous females, through which the exogenous genetic materials are transferred to
oocytes at fertilization. During this process, there is no need for ex vivo handling 
of embryos, which is strictly required for zygote-based gene modification such as
microinjection, EP, viral infection, and TransICSI. SMGT-AI, based on AI of sperm
that have been transfected in vitro with the exogenous DNA, is also a convenient
system for production of Tg animals, like TMGT. The CRISPR/Cas9 system, one
of the recently developed genome editing technologies, is now recognized as a
powerful and simple tool to create GM animals. More importantly, in this system, 
chromosomal integration of the genome editing components is not the prerequisite. 
Coupling this genome editing system with TMGT or SMGT-AI would accelerate
creation of genome-edited animals in a more convenient manner. Furthermore, 
TMGT/SMGT-AI will be particularly useful for other animals that are difficult to
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Abstract
Crops undergo artificially DNA modifications for improvements are considered 
as genetically modified (GM) crops. These modifications could be in indigenous
DNA or by introduction of foreign DNA as transgenes. There are 29 different crops
and fruit trees in 42 countries, which have been successfully modified for various
traits like herbicide tolerance, insect/pest resistance, disease resistance and quality
improvement. GM crops are grown worldwide and its area is significantly increas-
ing every year. Many countries have very strict rules and regulations for GM crops
and are also a trade barrier in some situations. Hence, identification and testing 
of crops for GM contents is important for identity and legitimacy of transgene to
simplify the international trade. Normally, molecular identification is performed at
three different levels, i.e., DNA, RNA and protein, and each level has its own impor-
tance in testing about the nature and type of GM crops. In this chapter, current
scenario of GM crops and different molecular testing tools are described in brief.
Keywords: biotechnology, genetic engineering, transgenic plants, molecular testing,
polymerase chain reaction, enzymes linked Immuno-sorbent assay
1. Introduction
Biotechnology is a set of scientific tools in which living organisms are used for
the welfare of mankind. This technique is efficiently used to modify and improve
plants, animals and other microorganisms to increase their value. Biotechnology
has a very wide range of applications and almost every field of daily science get
benefit from this technology. Application of biotechnology in the field of agriculture
has been practiced for a long time as people have wanted to improve agricultur-
ally important crops by selection and breeding. In 1970s with the advancements
in molecular biology, researchers were able to modify DNA which is a chemical
building block and specify the features of living organisms at molecular level. This
modification in genetic material or DNA is called as recombinant DNA technology or
genetic engineering [1]. With the involvement of genetic engineering in agriculture,
one can transfer useful hereditary/genetic information from distant sources into
targeted crop which was not possible through traditional breeding methods. This
genetic information is coded in the form of DNA or genes. Genes from any living



























































Genetically Modified Crops for
Biosafety and Legitimacy of
Transgenes 
Shahid Nazir, Muhammad Zaffar Iqbal and Sajid-ur-Rahman 
Abstract 
Crops undergo artificially DNA modifications for improvements are considered 
as genetically modified (GM) crops. These modifications could be in indigenous
DNA or by introduction of foreign DNA as transgenes. There are 29 different crops
and fruit trees in 42 countries, which have been successfully modified for various
traits like herbicide tolerance, insect/pest resistance, disease resistance and quality
improvement. GM crops are grown worldwide and its area is significantly increas-
ing every year. Many countries have very strict rules and regulations for GM crops
and are also a trade barrier in some situations. Hence, identification and testing 
of crops for GM contents is important for identity and legitimacy of transgene to
simplify the international trade. Normally, molecular identification is performed at
three different levels, i.e., DNA, RNA and protein, and each level has its own impor-
tance in testing about the nature and type of GM crops. In this chapter, current
scenario of GM crops and different molecular testing tools are described in brief. 
Keywords: biotechnology, genetic engineering, transgenic plants, molecular testing,
polymerase chain reaction, enzymes linked Immuno-sorbent assay 
1. Introduction 
Biotechnology is a set of scientific tools in which living organisms are used for
the welfare of mankind. This technique is efficiently used to modify and improve
plants, animals and other microorganisms to increase their value. Biotechnology
has a very wide range of applications and almost every field of daily science get
benefit from this technology. Application of biotechnology in the field of agriculture
has been practiced for a long time as people have wanted to improve agricultur-
ally important crops by selection and breeding. In 1970s with the advancements
in molecular biology, researchers were able to modify DNA which is a chemical
building block and specify the features of living organisms at molecular level. This
modification in genetic material or DNA is called as recombinant DNA technology or
genetic engineering [1]. With the involvement of genetic engineering in agriculture,
one can transfer useful hereditary/genetic information from distant sources into
targeted crop which was not possible through traditional breeding methods. This
genetic information is coded in the form of DNA or genes. Genes from any living













































   
 
Gene Editing - Technologies and Applications 
and transferred into other organisms to enhance their value. Organisms artificially
modified at genome level using genetic engineering tools are termed as genetically
modified organisms (GMOs). Microorganisms, i.e., bacteria and viruses have been
genetically modified for the production of different kinds of medicines, pharmaceu-
ticals and food ingredients [2]. Genetic engineering also has a great role in the field
of agriculture by developing the transgenic crops for various traits. For example,
a useful gene from bacteria, fungi and animals etc. could be isolated, cloned and
integrated into desired crop to develop resistance against diseases and pests, drought
and salinity tolerance or to improve the quality related traits etc. and are known
GM crops [3]. After transformation, the transgenes replicate with indigenous plant
genes and produce specific protein [4]. Biotechnology supports in practical exploita-
tion of genetic material for the betterment of mankind. By using latest trends in
genetic engineering one can create the new face of existing cultivars with improved
and desirable characteristics. In addition to the improvement of agronomic traits,
scientists are also looking in the production and expression of commercially valuable
protein in plants like spider silk protein and polymers used in surgery [5]. A huge
number of human vaccines, antigens and other pharmaceutical products are very
efficiently expressing in transgenic plants. GMO offer many benefits to humans, but
at the same time people also worry about the possible threats of using GMOs. These
risks include the possible introduction of allergens in GM foods and transfer of selec-
tion marker genes which are normally antibiotic resistant genes to gut flora [6–8]. 
With the introduction of foreign genes, there are also some biosafety issues linked
with GM crops. Such crops are often unintentionally or intentionally used for food and
feed production. In some conditions, GM crops spread globally by trading, transporta-
tion and storage either intentionally or unintentionally and contaminate GM free items.
Many countries have very strict rules and regulations for the development, cultivation,
commercialization and labeling of GM crops and is also a trade barrier in some situations
[9]. For example, USA has an optional labeling of GM in food items, whereas European
Union has very strict rules for approval, cultivation and use of GM crops, including a
compulsory labeling system [10]. They require very comprehensive information about
such crops like type of targeted crop and transgene, safety for humans, environment,
animals and effects on other related non-modified crops [11–13]. The increase in GM
crop production has been coupled with an intricate and asynchronous international
regulatory approval system, requiring identification and testing of food and agricultural
products for the presence of GM content to simplify international trade. Molecular
identification of GM crops confirms the identity and type of modified product at each
stage and assures compliance with import for GM food and feed [14]. The testing of GM
crops could be performed in open field or under controlled laboratory conditions that
depends upon type of samples and sensitivity of test performed. Normally, molecular
identification and testing of GM crops is performed at three different stages, i.e., DNA,
RNA and protein. Each testing level has its own importance in testing the nature and
type of GM crops. Generalized GM development methodology, global status, testing
methods, possible biosafety issues and other benefits etc. are discussed in brief. 
2. Global scenario of GM crops 
The rapid acceptance of GM crops shows the significant benefits realized by
large and small growers in both developed and under-developed countries growing
GM crops commercially. Around 99% of global GM crops area is occupied by four
major crops, i.e., soybean, maize, cotton and canola. USA is leading in the area
under GM crops with 75.0 million hectares followed by Brazil and Argentina with
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million hectares with an increase of 3.0% than 2016 [15]. Despite the possible
health risks, cultivation area of GM crops is regularly increasing and introduc-
tion of new GM crops is continued. There are 29 different crops and fruit trees
in 42, which countries have been successfully modified for various traits. A brief
detail of GM crops, targeted/GM traits, number of GM events with responsible
transgenes has been given in Table 1. Among GM trait distribution, herbicide
Table 1.
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tolerance (HT) enjoys the top position with 47% of the GM crops area. Stacked
traits and insect resistance (IR) occupy 41 and 12% of the cultivated area of GM
crops in 2017, respectively. The cultivation area under stacked traits, i.e., HT/IR is
increasing very fast and various stacked gene products were got approved for food/ 
feed and general commercialization. Soybean, maize and cotton are major crops
developed with stacked traits [16]. Countries approving GM crops for food, feed
and general cultivation are also increasing every year. In year 2017, 18 countries
issued 176 approvals regarding GM crops cultivation, commercialization and use
as food/feed [15]. 
3. GM crop’s development methodology 
Plants, in which one or more foreign genes are introduced artificially instead of
plant getting them under natural conditions of cross-breeding or normal recombi-
nation, are known as GM plants. The introduced gene, known as transgene, could
be from identical species or from different species within the same kingdom or
other kingdom [17]. The process of introducing the transgene is called as genetic
transformation that has become an important tool for crop improvement. Different
steps are involved in the genetic transformation work like selection and identifica-
tion of gene of interest (transgene), isolation from source organisms, cloning into
suitable plasmid vector. Followed by development of expression vector containing
all regulatory elements, i.e., promoters and terminators for regulation of transgene
expression in targeted plants [18]. In addition, another gene cassette of selec-
tion is also the part of expression vector which serves as the primary selection of
putative transgenic cells on artificial plant media. Normally two types of selection
markers are used, antibiotic and visual selection markers, which depend upon the
type of work. Final expression cassette is multiplied in suitable bacterial media
and verified using various molecular biology techniques before transformation
[19]. Integration of final expression cassette into plant can normally be achieved
by two methods: (i) direct DNA delivery system, i.e., using biolistic gene gun by
coating DNA on gold or tungsten particles and shooting on plant tissue with a
specific pressure of helium gas (ii) introduction of gene by using biological vectors
like disarmed Ti-plasmid of Agrobacterium tumefaciens. Both methods have suc-
cessfully been used for the introduction of transgenes in plants [20]. Following
genetic transformation, the transformed tissues are initially screened for transgene
integration using selective plant tissue culture media. The regenerated plantlets on
selective media supposed to have the transgenes and called as putative transgen-
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true transgenics (ii) escapees (iii) mutants. Hence, various molecular biological
techniques like PCR, blotting, Enzyme-linked ImmunoSorbent Assay (ELISA)
etc. are used to confirm transgene integration and true transgenics. The overall
methodology for gene isolation, cloning, transformation and selection of putative
transgenics has been shown in Figure 1. 
4. Molecular test methods for the identification of GM crops 
Introduction of GM crops and their products in markets required to be monitored
and need to know the presence and type of GM elements. Labeling rules and trade
requirements vary from country to country which necessitates for the development
of reliable methods for the detection, identification and quantification of GM crop
varieties and their products. GM crops can be tested by identifying either transgenes
at DNA level, at transcriptional level by mRNA of transgene or using resulting trans-
protein. There are many other methods like chromatography and mass spectrometry
etc. which have their own importance in GMO testing. An overview of test methods
used for detection and identification for GM crops has been given in Figure 2. Every
test method has its own significance and value towards the final conclusion of GM
crops. A brief summary of these methods has been shown in Table 2. 
4.1 DNA based test methods 
There are three main types of DNA based GMO testing methods. 
4.1.1 Qualitative PCR 
Polymerase Chain Reaction (PCR) is a primary method for screening of GM 
crops at DNA level. Qualitative analysis comprises of specific detection of target
DNA sequence in test samples. Qualitative results clearly validate the presence or
absence of GM elements under study, comparative to suitable controls and within
the detection limits of analytical technique used, and test portion analyzed [21, 22]. 
This method has found very broad and wide applications in GMO detection as com-
monly accepted tool for regulatory purposes. In this method target gene/GM ele-
ment multiplied to millions or billions by using gene specific primers. PCR process
is basically comprised on three main steps, i.e., denaturation, annealing and exten-
sion in one cycle. In first step the double stranded DNA is separated into two single
strands, primers then identify their homologous sequence and are annealed to each
strand in second step. Third and final step involves making two identical copies of
original DNA strand by adding exact nucleotides with the help of DNA polymerase
at an appropriate temperature. These cycles repeated normally 40–50 times which
results in an exponential amplification of target DNA/gene. Amplification of target
gene occur in-vitro through a reaction catalyzed by a DNA polymerase in the pres-
ence of oligonucleotide primers and deoxyribonucleoside triphosphates in a defined 
reaction buffer [23, 24]. This amplified DNA can be visualized by using gel electro-
phoresis techniques. The results of this method will be either positive or negative
for specific GM elements. 
There are four testing methods which includes (i) Target-taxon specific (ii) 
Screening (iii) Construct-specific and (iv) Event-specific, these methods are gener-
ally used for the detection and identification of GM crops using PCR. Selection
of specific and suitable primers is the most critical step in GMO detection which
depends upon the testing method used. Brief detail of qualitative PCR based testing 
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Figure 2.
Diagrammatic presentation of molecular test methods of GM crops. 
4.1.1.1 Target-taxon specific method 
PCR with various barcoding methods normally used for plant identification
from mixed food samples particularly prepared from different plants. DNA barcode
is broadly used technique for the detection and identification plants, animals or
fungi texa by sequencing an optimized short DNA fragment. PCR and barcoding 
approaches identify specific texa very intelligently within samples of different
origins [25–27]. This approach also plays very important role in the detection of
mislabeled species and accidental or intentional species exchanges in food samples
[28, 29]. The success of this method for identification and detection of species
depends on the selected loci, because DNA barcode constitute a small portion of
genome coupled with other PCR limiting factors, no single locus has been selected 
as universal DNA barcode region for all plant identification. For example lectin gene
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Table 2.
Brief summary of GMO test methods. 
DNA sequences in plants [31], polygalacturonase gene (PG gene) codes for a
PG-enzyme that is linked with ripening in GM Zeneca tomato etc. [32]. 
4.1.1.2 Screening method 
This is a most generalized method and widely used for the screening of GM crops
from non-GM materials. This is not crop specific and can detect the GM elements even
in raw and processed matrices like food and feed products developed from GM crops. In
this method promoter, terminator and selection marker genes are the target elements in
PCR. These are the bacterial gene sequences used to regulate the transgenes and selec-
tion of transgenic cells on artificial plant media [33, 34]. These genetic elements include
cauliflower mosaic virus CaMV 35S promoter, Agrobacterium tumifaciens nopaline
syhnthase NOS terminator and neomycin phosphotransferase NPTII etc. present in
most commercialized GM crops in market. Hence, one can easily detect and identify the
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4.1.1.3 Construct-specific method 
In this method specific primer pairs normally got designed from the trans-
formed gene construct. These construct could be transformed more than one crop
for genetic improvement. The construct-specific detection method involves target-
ing the junction between two elements, and it is not able to distinguish two differ-
ent events transformed with the same plasmid [37]. These methods either DNA or
protein based. For practical reasons, several DNA sequences are shared by many
GM crops and protein based methods detect the product of inserted DNA like Bt
toxin in GM crops. Since different GM crops may produce the identical protein, this
test method can detect a sample for several GMOs in one step. For examples GTS-
40-3-2 GM construct for the development of roundup ready soybean, Zeneca F282 
GM tomato, Bt11, Bt176 and T25 for GM maize etc. 
4.1.1.4 Event-specific method 
The junction sequences in the transgene integration points in the plant genome
can be used to identify and detect the specific transformation event. The transgene
integration site usually unique and specific for each transformation event due to
lack of homologous recombination. Hence, different GM crops could be produced 
with similar gene construct and this event-specific detection method will be the
only approach to differentiate between GM crops having similar transgenic cassette. 
This method can distinguish legitimate transgenic events from related unauthor-
ized genotypes/varieties having identical transgene construct, thus this approach
frequently used to assess the legality of GM crops [24]. Examples are Mon-531 event
for Bollgard cotton, Mon-1445 event for Roundup Ready cotton, Mon-89,034 event
for YieldGard VT Pro maize etc. 
4.1.2 Southern blotting 
Another DNA based GM crops identification techniques is southern blotting 
which was described by Southern in 1975 [38]. This test method is frequently used 
for the identification of specific DNA fragments transformed into the genome of
transgenic plants or its products. This method could also be used in gene discovery
and mapping, evolution and developmental studies, diagnostics and forensics etc. 
This test method involved five steps (i) DNA isolation and enzyme restriction (ii) 
electrophoresis for DNA separation (iii) shifting and fixing of separated DNA 
on suitable membrane (iv) hybridization with labeled probe and (v) detection
by chemiluminescence or radioactive methods. This is very reliable method that
provides the molecular evidence of the transgene integration and also estimates the
copy number of introduced gene into the GMO genome. In comparison with PCR, 
this method associated with some limitations like it requires large amount of DNA, 
expensive, requires more time, proper infrastructure and trained manpower etc. 
4.1.3 DNA microarray 
A microarray is a laboratory method used to identify the expression of more
than one gene in a single test. It is DNA based and new in comparison to previous
protocols. This test method has been included in GMO screening as a method for
simultaneous detection of more than 250,000 targets in single assay/chip [39–41]. 
This method consists of pre-amplification step of the desired targets, followed by
hybridization on a chip having specific probes, and then detection step [42, 43]. 
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Use of microarray technology for the GMO detection is restrained as it require very
special and costly equipment for scanning microarrays, chances of cross contami-
nation and laborious in comparison with other techniques. 
4.2 RNA based test methods 
Transgenic DNA must be translated into protein to be an effective and have
effects in an organism. This translation process occurs when DNA transcribed into
messenger RNA (mRNA), and is considered as the intermediate step transferring 
information contained in DNA to protein. The presence of mRNA is directly associ-
ated with gene expression. Different molecular biology techniques used to monitor
and study the gene expression in GMOs include real-time PCR, northern etc. These
methods could be used to identify the transgene expression in various plant tissues
and at different developmental phases in GMOs. 
4.2.1 Quantitative real-time PCR 
Gene expression normally verified in RT-PCR using isolated mRNA from
GMOs. This test method is based on reverse transcription of mRNA and synthesis
of complementary DNA (cDNA) which is then used as template in PCR amplifica-
tion of target gene. The amplified fragment electrophoresed and visualized using 
agarose gel under UV. Intensity of amplified band in agarose gel give some indica-
tions of target mRNA in tested sample [44]. Quantitative RT-PCR is an up-to-date
method, principally based on RT-PCR and is generally known as qRT-PCR. It is
more robust, specific and sensitive, provides good quantitative results. The process
of amplification is presented in real-time by capturing a fluorescent signal in more
sophisticated way. In real-time assay of transgene in GMOs, the amplification and 
detection occur simultaneously [45]. 
4.2.2 Northern blotting 
Similar to RT-PCR, northern blotting also requires mRNA as tested material from
GMOs. This is a standard method for the analysis of size and level of target RNA in a
complex GMO samples. Likewise southern blotting, it also composed on five steps,
only difference is that the starting material is mRNA instead DNA and the labeled
probe is complementary DNA (cDNA), which hybridizes the RNA. It gives compara-
tive amount of gene expression at the RNA level. This is comparatively simple to
perform, cheap and not overwhelmed by artifacts [46]. Recent advancements of
hybridization membranes and buffers have resulted in increased sensitivity, closing
the gap to the more laborious nuclease protection experiments. It is considered that
this test method can study gene expression for a limited number of genes per analy-
sis. This can be very useful to monitor the up- or down regulation of transgene for
specific problem, but is not useful in monitoring the up- or down regulated genes are
unknown. 
4.3 Protein based test methods 
Immunoassay protocols for the detection of GMOs by antibodies are the impres-
sive for the detection of various types of proteins either qualitatively or quantita-
tively [47]. Two types of antibodies, i.e., monoclonal and polyclonal could be used 
depending on the need and specificity of detection method. Normally, Enzyme-
linked ImmunoSorbent Assay (ELISA) and western blot methods have been used 
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4.3.1 Qualitative strip test 
Most common antibody based test for GMO screening is strip test method
also known as lateral flow or dipstick test. It is qualitative in nature and gives the
information about the presence or absence of specific proteins in tested samples. In
this method, thin strip made-up of nitrocellulose membrane used which protected
by a sample pad on one end and a wicking pad on other end. Test samples normally
homogenized in suitable buffer solutions and membrane on strip wicks up the
solution and it will move upward via capillary movement and protein will bind to its
specific antibody. The results shown in the form of visible lines on the strip depict-
ing that the specific protein is present in test sample. There are normally two lines
appears on the strip, one for tested protein and second of control line showing the
authenticity of all test procedure and strip used. The appearance of only control line
on the strip, shows that sample is negative for transgenic protein, but the test was
performed accurately [48]. This is very quick method to test GMOs which normally
take 5–15 minutes to gives results [49]. In addition, it is cheap, easy to perform and
not require specific equipment and special trained manpower. It can be performed
in open field as well. Currently, strips are available to detect multiple proteins in
single assay [50]. 
4.3.2 Quantitative ELISA test 
Another more sensitive antibody-based protein identification method is
Enzyme-linked ImmunoSorbent Assay (ELISA) also called a plate test or quantita-
tive ELISA. It gives information about the quantity of protein in tested samples.
In this assay protein specific antibody coated multi-well plate is used to identify
and quantify the specific protein. Specific protein present will bind to antibody,
following washing, another antibody specific for protein of interest and tagged
with an enzyme is added to well [51]. The enzyme linked identification antibody
will bind with specific protein and unbound antibody removed by washing. The
color of the solution will change from blue to yellow by the addition of substrate
for enzyme. Intensity of yellow color is directly proportional to amount of protein
present in well. This GMO test method is more sensitive in comparison with strip
test and can detect target protein even in very low concentrations. However, it
requires more time, trained manpower and good laboratory facilities in contrast to
strip test. 
4.3.3 Western blotting 
This is very specific method and provides the qualitative results of the target
protein in GM crop sample. This method is very useful to analyze the insoluble proteins
[47, 50]. Like other blotting techniques samples are solubilized with detergents and
reducing agents and separated by electrophoresis and shifted to membrane. Binding
immunoglobulin sites on membrane are blocked by dried nonfat milk and specific
sites are probed with antibodies. Detection carried out using different staining agents
silver nitrate of Coomassie, alkaline phosphatase etc. [18]. Its detection limit varies
with test ample like 0.25% for seeds and 1.0% for toasted meal [52]. In comparison
with other protein based assays, it is difficult method, and is capable of studying only
a few samples at a time. Therefore, it is not frequently used in GMO testing activities
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5. Certified/standard reference materials for GMO testing 
Validity and authenticity of GMO testing results is doubtful until the use of
positive and negative controls at each testing step. Use of certified reference material
(CRM) or standard reference material (SRM) during testing produce not only vali-
date the testing results but at the same time, assess the performance of test method,
equipment, personnel and other environmental conditions in which testing being
performed [52]. CRM must contain the certificate of analysis, should be prepared by
following ISO-Guide 34, have information about which GM events or elements pres-
ent and what is its concentration, storage requirements, preparation and expiry date
etc. While SRM have all the similar information but lacks the certificate of analysis
and was not prepared by a certified company. Bothe CRM and SRM could be used
to validate the testing results but CRM is more reliable and globally acceptable. Each
GMO needs specific CRM which is used in testing and conclusion about the presence
of specific GM event/element in testing samples. Normally seeds of GM and Non-GM
crops are mixed at specific percentage and homogenized to make powder before
analysis [51]. The availability of CRM is presently restricted due to some concerns of
IPR and expenses [53]. The Institute of Reference Materials and Measurements at the
Joint Research Center (JRC) in Geel, Belgium, FAPAS Fera Science Ltd., Sand Hutton
UK, American Oil Chemists Society (AOCS), Urbana, Illinois, USA etc. are autho-
rized companies to paper and sale of CRMs for GMO testing. 
6. Pros and cons of GM crops 
The most common improvement by the introduction of GM crops is the increase
in yield and quality. There are many yield limiting factors like insect/pest, diseases, 
drought, heat, salinity, rapidly changing climatic conditions etc. Conventional 
approaches like irrigations, sprays and use of fertilizers etc. done a great job but
the problem was increasing day-by-day. By the introduction of recombinant DNA 
technology in agricultural sector, scientists successfully develop the new face
of existing cultivars with improved and desirable traits. The GM technologies
increase the opportunities for plant breeders to develop crops that are protected 
from climatic stresses and attacks of insects and diseases [54, 55]. The crops have
been successfully modified for herbicide tolerant, insect/pest resistance, disease
resistance, abiotic stress tolerance, micronutrient enrichment etc. Furthermore, this
technology helping us to improve the nutritional quality, longer shelf life, foods that
are more appealing to eat and easier to transport. Development of various biophar-
maceuticals and expression of human therapeutic proteins in plants also a great
contribution of GM technology to improve the human life [56]. 
On the other hand there are also some biosafety issues linked with the use of GM 
crops. Biosafety means the need to protect human and animal health from pos-
sible adverse effects of GM technology. There are some reports about the potential 
threats linked with the use of GMOs like risks of allergineicity, development of
herbicide tolerant weeds and resistant insects, harms to non-target organisms, 
selection marker gene could induce antibiotic resistant and reduce the effectiveness
of antibiotics to cure disease etc. [7, 57–58]. Turning on of certain genes due to the
use of strong promoters and might be harmful in humans, effects on the nutritional 
profiling, transgene may flow from non-target crops/weeds etc. Biosafety is an
essential to modern biotechnology and the adoption of biotech products requires
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stakeholders and dissemination of information and knowledge in public about GM 
products is much important to safe use of this technology. 
7. National scenario of GM crops, biosafety, labeling and trade aspects 
Agriculture sector of Pakistan plays a dominant role in the economy with 18.9%
contribution in Gross Domestic Product (GDP) and engages 42.3% labour force. It is
also a chief source of foreign exchange earnings and provide raw material for prog-
ress of other sectors [59]. Pakistan stands at seventh position among 26 countries
growing GM crops, and insect resistant GM cotton of Mon-531 event is the only crop
grown in the country with adoption reaching 2.9 million hectares of total 3.0 million
hectares cotton crop area. Mon-531 is the only approved commercialized GM event
in the country having insecticidal Cry1Ac gene of Bacillus thurengiiensis to control the
lepidopteron insects. In 2015, US$398 million economic gain was estimated with the
adoption of GM cotton [60]. Moreover, field trials of GM maize hybrids have suc-
cessfully been conducted for single and stacked insect resistant (IR) and herbicide
tolerances (HT) traits. For single HT trait, Monsanto event NK-603 was tested, while
for stacked traits, i.e., IR/HT, Mon-89,034 x NK-603, TC-1507 x Mon-810 x NK-603
and TC-1507 x NK-603 were studied. These GM traits were officially approved for
commercial cultivation by National Biosafety Committee in 2016. Field performance
trials were completed as the part of regulatory requirements and varietal registration
by Federal Seed Certification and Registration Committee of National Food Security
and Research ministry [15]. In near future, GM maize having IR and HT traits will be
grown by farmers, and it will be the second approved GM crop in the country. 
Pakistan is signatory toWorld Trade Organization (WTO) and has sanctioned
Convention on Biological Diversity (CBD) in 1994 and Cartagena Protocols in 2009.
Different legislations under the Agreement of Trade Related Aspects of Intellectual
Property Rights have been disseminated in the country. In addition, Pakistan Biosafety
rules were designed in 2005, which are responsible for safe use of GM technology, manu-
facturing, import and storage of GMOs. Following these, National Biosafety Guidelines
were developed in which the procedures to undertake all linked activities to GMO work
were highlighted. These guidelines were framed in accordance with the recommenda-
tions of Food and Agriculture Organization (FAO), World Health Organization (WHO),
United Nations Industrial Development Organization (UNIDO) and United Nations
Environment Programme (UNEP). As per these guidelines the biosafety aspects of GMO
work are monitored at three different levels, i.e., Institutional Biosafety Committee
(IBC), Technical Advisory Committee (TAC) and National Biosafety Committee (NBC).
The applications related to GMO work are submitted to IBC, and after thorough evalu-
ation, the case is submitted to TAC for assessment and recommendations, while NBC is
the final body to take further action regarding its approval or rejection. NBC is respon-
sible to looks after the laboratory research, field studies, commercial release, imports,
exports and sale/purchase of GMOs and their products [61]. 
Pakistan exports rice, cotton, fruits (oranges and mangoes), vegetables and fish
to its neighboring states, Middle East and Central Asian countries. IR cotton of
Mon-531 event is the only one GM crop officially approved for general cultivation in
the country. Very comprehensive testing procedures are adopted to test and verify
the status of approved events in the candidate cotton varieties. Around 49 universi-
ties and 07 research institutes are actively involved in the teaching and research
related to the development and testing of GM crops in the country [62]. In Pakistan, 
Agricultural Biotechnology Research Institute (ABRI) at Ayub Agricultural 
Research Institute (AARI), Faisalabad and SGS Laboratories Karachi have GMO 
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(PNAC) for ISO-17025. These labs are efficiently working on the testing and 
identification of GM crops and are equipped with state-of-the-art facilities needed 
for the detection, identification and quantification of GMOs. All crop seeds being 
imported from other countries are first tested for the presence and type of GM 
elements from these laboratories and then allowed for cultivation in the country. All 
the import and export activities are strictly monitored with reference to GMOs. 
8. Conclusion 
Testing of GM crops is important issue for the legitimacy, biosafety and regula-
tory purposes. The area under GM crops is increasing very rapidly and many new
genes are being introduced in major crops. For the safety of humans, environment, 
animals and other related micro-flora, a comprehensive molecular testing of newly
developed GMO is very important before commercial release. Regulatory processes
for GM crops approval need comprehensive risk analysis for each case separately. 
The detection and identification of GMOs is also of great value in identifying the
purity of sample, labeling food and trade reasons. Therefore, combined use of more
than one testing methods would be advantageous for complete analysis, authentic-
ity and biosafety assessment of GM samples. 
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Edited by Yuan-Chuan Chen and Shiu-Jau Chen 
Gene-editing technologies (e.g., ZFNs, TALENs, and CRISPRs/Cas9) have been 
extensively used as tools in basic research. Tey are further applied in manufacturing 
agricultural products, food, industrial products, medicinal products, etc. Particularly, 
the discovery of medicinal products using gene-editing technologies will open a 
new era for human therapeutics. Tough there are still many technical and ethical 
challenges ahead of us, more and more products based on gene-editing technologies 
have been approved for marketing. Tese technologies are promising for multiple 
applications. Teir development and implications should be explored in the broadest 
context possible. Future research directions should also be highlighted. In this 
book, the applications, perspectives, and challenges of gene-editing technologies are 
signifcantly demonstrated and discussed. 
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